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Chronic kidney disease and end stage renal disease 
Kidneys in all the vertebrates play a central role in overall homeostasis of the 
body. Main function of the kidney is to purify blood via glomerular filtration 
and excrete waste products in urine. Kidneys also play an eminent role in 
maintaining blood pressure, acid-base homeostasis, electrolyte balance and 
have a variety of endocrine functions, such as the production and secretion of 
erythropoietin for regulation of blood hemoglobin levels. 
Many different direct or indirect insults can lead to chronic kidney disease 
(CKD), which over time may progress to end stage renal disease (ESRD). 
ESRD is the terminal stage of kidney disease. The common clinical signs of 
progression towards ESRD are a progressive decline in glomerular filtration 
and abnormal glomerular protein leakage (1). Proteinuria is not only a marker 
of renal damage but also a mediator of the progression of renal disease. In 
overtly proteinuric conditions, the non-physiological presence of proteins 
activates tubular epithelial cells. Activated tubular cells induce pro-fibrotic- and 
pro-inflammatory signaling and cells, which lead to tubulo-interstitial damage 
and progression of CKD (2-4). Once kidneys fail, renal replacement therapy 
(RRT) is necessary for survival of patients. Dialysis and kidney transplantation 
are the two available forms of RRT. If feasible, kidney transplantation is 
preferred over dialysis in terms of survival and quality of life (5,6).  
 
Chronic transplant dysfunction  
The first renal transplantation was successfully performed in 1954 in identical 
twins, in which no immunological barriers exist. After that, it took many years 
to find immunosuppressive regimens that allowed for performance of renal 
transplantation between donors and recipients that are not genetically identical. 
Since then, much improvement has been achieved in both short and long term 
graft survival (7). However, the pace of improvement in long term graft 
survival is strongly lagging behind the improvements in short term graft 
survival (8). The main causes of late graft loss are death with a functioning 






decline in kidney function in the presence of high blood pressure and 
proteinuria, typically occurring beyond the first 3 months after transplantation. 
The histological hallmarks of CTD are glomerulosclerosis, transplant 
arteriosclerosis and interstitial fibrosis with tubular atrophy (9). Transplant 
arteriosclerosis is characterized by neo-intima formation within the arterial 
vasculature in the transplanted organ, that leads to thickening and hardening of 
vessels, that in severe cases can ultimately lead to occlusion of the vessel lumen 
(10). The progressive luminal occlusion leads to reduced blood supply and 
ischemic injury. The etiology of CTD is not clear. It is, however, recognized to 
be a multi-factorial process. Both immunological and non-immunological 
factors contribute to the development of CTD (11). The major known risk 
factors of CTD are summarized in table 1, by a break-up in immunological and 
non-immunological risk factors. It is noteworthy that many of the non-
immunological risk factors for CTD are also cardiovascular risk factors, such as 
hypertension, dyslipidemia, diabetes etc. Smoking is also a very well-
established cardiovascular risk factor, but its role in CTD has not been well-
established. In this thesis, we investigate the hypothesis that smoking is an 
important additional risk factor for CTD. 
 
Table 1: Major risk factors associated with chronic transplant dysfunction 
 









Non-immunological risk factors 
Recipient race, age and sex  
Donor age, sex, health status 
Duration of dialysis 

























Smoking: past, present and future  
Smoking of tobacco is a very old practice. Rodrigo de Jerez and Luis de Torres 
first introduced tobacco to Europe in 1492 and it is in use ever since. Only 
recently, adverse health effects of smoking were recognized and lead to strong 
anti-smoking awareness. As a consequence, the prevalence of smoking in the 
USA general population declined from 42% in 1965 to 25 % in 2000. Despite 
these falling trends, many people are still smoking (e.g. 46 million still continue 
smoking in the USA alone). This poses them at substantial risk for 
cardiovascular and chronic diseases in 2005 (12). Currently the prevalence of 
smoking in the world varies between 40 and 6 %. In 2010 The Global Tobacco 
Survey was done in China. It was found that 28.1% of Chinese population was 
smoker with a huge male dominance, as exemplified by a male to female ratio 
of 22:1 (13). Smoking is highly addictive and therefore it is very difficult to 
quit smoking. However public policies are made widely to discourage the use 
of cigarette smoking. Many initiatives are underway. In England for example, 
the smoking toolkit study (STS) has been designed to evaluate longitudinal 
trends in cigarette smoking cessation. The first data from this study are 
expected by 2014 (14).    
 
Smoking and chronic diseases 
Smoking is an acknowledged risk factor for different forms of cancer and 
several chronic diseases. Among cancer, strongest associations exist with lung 
and bladder cancer (15-17). Smokers have a 20 times higher risk of lung cancer 
than non-smokers (18). Among chronic diseases, the strongest association of 
smoking exists with chronic obstructive pulmonary disease (COPD), a major 






than non-smokers (19,20). Smoking is also an established risk factor for 
cardiovascular disease (21-23). In the large INTERHEART study, smokers had 
an odds ratio of 2.87 for myocardial infarction compared to non-smokers (24). 
 
Smoking as a risk factor for kidney diseases 
Smoking has recently been identified as a renal risk factor as well. Smoking is 
found to be associated with kidney injury both in the general population and in 
the patients with elevated risk for kidney disease. In a cross-sectional analysis 
of the Prevention of REnal and Vascular ENd stage Disease (PREVEND) 
study, it was found that smoking is associated with albuminuria in the general 
population (25). It has also been shown that smoking is associated with 
albuminuria in hypertensive patients (26). Data from the Multiple Risk Factor 
Intervention Trial (MRFIT) showed a dose dependent relation between cigarette 
smoking and risk of development of ESRD in the general population (27). 
Furthermore, in patients with diabetic nephropathy it has been shown that 
kidney disease progresses twice as fast in smokers as in non-smoking patients 
(28). Likewise, smoking has been shown to be a risk factor for progression of 
IgA nephropathy (29-33). 
Interestingly, all these observations involve native kidney diseases, in which the 
kidney is fully innervated. One of the contemporary theories is that the 
detrimental effects of smoking on kidneys is through the action of nicotine on 
the sympathetic nervous system, thereby inducing intrarenal vasoconstriction 
and parenchymal ischemia (30,34,35). It should be noted that the kidneys of 
renal transplant recipients are denervated. As such, they could be protected 
from the adverse effects of smoking by this hypothetical pathway. So far, no 
studies have been performed in RTR. In chapter 2 of this thesis we 
investigated the risk of mortality and graft failure associated with smoking in a 
stable renal transplant cohort.  
Another population of interest in this perspective is that of lung transplant 
recipients. Progressive renal damage is common in this population with a major 
role of CNI required for lung graft survival. Also, early per- and peri-operative 




hemodynamic instability is a likely contributing factor. As smoking is a main 
progression factor in chronic pulmonary disorders, many patients that require a 
lung transplant have a history of heavy smoking. However, they have to stop 
smoking before being considered for transplantation. This population is 
therefore suitable to investigate the effects of former smoking in terms of 
mechanisms. Activation of renal nerves could at first lead to a 
hemodynamically mediated decline in renal function due to vasoconstriction, 
but eventually cause tubulo-interstitial injury due to chronic ischemia. 
Therefore if a current vasoconstrictive effect of nicotine is the main cause of the 
association of smoking with impaired renal function, one would not expect an 
association of former smoking with chronic kidney disease these patients suffer 
from. If, however, the effect is mediated by other toxic effects, former smoking 
could still be associated with renal disease in these patients. In chapter 3 of this 
thesis we describe the investigations that we performed on this topic in the lung 
transplant cohort of our hospital. 
 
Alcohol consumption and mortality 
In our studies on smoking in RTR we found a positive association of smoking 
with alcohol consumption. This is an association that has also been found in 
other populations (36). Along with cigarette smoking alcohol is a usual part of 
social gatherings, dinner and parties. Excessive intake of alcohol is called 
alcoholism and leads to conditions like malnutrition, laryngeal cancer, 
esophagus cancer, depression, liver cirrhosis and liver cancer (37-42). Mild 
alcohol intake, however, is known to be beneficial for survival in the general 
population (43,44). In the general population, alcohol usage and mortality show 
a J shaped curve, with mild users protected compared to non-users and heavy 
users (45). Also, the relation of alcohol consumption with cardiovascular 
disease has been widely studied. A Danish study showed an inverse association 
between alcohol consumption and risk of coronary artery disease (46). They 
showed that in moderately drinking men, risk of coronary artery disease was 






consumption in renal transplant recipients. One study found an increased risk of 
graft failure in recipients with alcohol addiction pre-transplantation (47). One 
other study reported on the prevalence of social alcohol consumption post-
transplantation (48), but to the best of our knowledge no studies exist on a 
potential association of post-transplantation alcohol consumption with graft 
failure or mortality. In chapter 4 of this thesis we investigated the association 
of smoking with alcohol consumption in RTR on one hand and the influence of 
smoking and alcohol consumption on graft failure and all-cause mortality on 
the other hand.  
 
Nicotine  
In the second part of this thesis, we aimed to more closely investigate the effect of 
nicotine on CKD. Nicotine is one of the best known and the most abundant component 
of cigarette smoke. Nicotine is obtained from tobacco and highly addictive in nature. 
Once inhaled or taken in oral form as snuffs or chewing gum or used in the form of 
dermal patch, nicotine rapidly reaches the liver and the brain. Nicotine binds to the 
nicotinic acetylcholine receptors (nAchR) (49,50). To date, 17 nAchRs have been 
described. Nicotine binds to various subtypes of nicotinic acetylcholine receptors 
present in central and peripheral nervous system.(51)The addictive nature of nicotine is 
due to immediate reward from the brain dopaminergic pathways (52,53). Nicotine is 
metabolized by cytochrome P450 enzymes of the liver into various metabolites. 
Nicotine and its metabolites are excreted from the body in urine, in stool or by 
exhalation (54).  
In humans nicotine replacement therapy (NRT) forms the first line of therapy to 
support smoking cessation and to reduce the withdrawal symptoms of quitting 
smoking. NRT is a controlled way of delivering nicotine to break the reward cycle 
from nicotine in cigarette smoke. Randomized control trials have shown that all forms 
of NRT have added beneficial effects for long-term abstinence from cigarette smoking. 
 
Nicotine and inflammation 
Recent literature showed that nicotine possess anti-inflammatory properties 
(55-57). Nicotinic receptors are also present on monocytes and endothelial 




cells. Activation of these cells is crucial for sustained inflammation. The anti-
inflammatory effects are largely mediated through a7-nAchR. Binding of 
nicotine to the a7nAchR present on endothelial and macrophages leads to 
deactivation of those cells and thereby down-regulation of inflammation. In line 
with these actions, nicotine has been found to be associated with a more 
favorable prognosis in many observational studies of diseases of inflammatory 
origin, e.g. Ulcerative Colitis, pneumonitis, and arthritis (58). In animal models 
nicotine attenuates ischemia-reperfusion-induced kidney damage (59-61). Thus, 
whereas nicotine has been suggested to be a “nephrotoxic” component of 
cigarette smoke by inducing intra-renal vasoconstriction and renal ischemia 
(62,63), it could also have renal protective properties by ameliorating intra-
renal inflammation, as the latter is assumed to be involved in progression of 
CKD, as outlined below. 
 
Proteinuria and kidney inflammation 
Intrarenal inflammation is involved in many, if not all types of progressive 
renal damage. In some renal conditions an inflammatory disorder is the primary 
trigger for renal damage, such as ischemia reperfusion injury, or 
glomerulonephritis. However, in many CKD patients no such specific primary 
disorder is present, but nevertheless inflammation is relevant to progressive 
renal function loss. As stated above, proteinuria is a main clinical risk factor for 
progression of CKD, by a sequence of events that involves glomerular protein 
leakage as well as tubulo-interstitial inflammation. Excess presence of proteins 
in the renal tubules leads to tubular uptake of the leaked proteins and hence 
activates the tubulo-interstitial cells to secrete inflammatory cytokines (64). 
Persistent inflammation can lead to irreversible damage with extra-cellular 
matrix deposition and scarring of tissue. The monocyte-macrophage system 
plays an important role in this process (65). The damage caused by uncontrolled 
inflammation may in turn aggravate proteinuria (66). This vicious cycle when 
not broken will lead to rapid progression towards ESRD. Possible interventions 






drugs or with calcineurin inhibitors. In inflammatory kidney diseases such as 
IgA nephropathy or primary glomerulonephritis, such treatments can be 
successful in selected patients (67). Long term treatment however is limited due 
to side effects such as increased susceptibility to infections. Moreover, 
calcineurin inhibitors have also direct renal adverse effects like interstitial 
fibrosis, tubular atrophy and medial arteriolar hyalinosis (68). Therefore, the 
currently available interventions targeting the inflammatory component of the 
progressive CKD have not gained wide acceptance, and it might be worthwhile 
to investigate new anti-inflammatory therapies. In chapter 5 of this thesis, we 
therefore investigated the renal effects of oral nicotine in a rat model of 
spontaneous proteinuria.  
 
Neointima formation and end organ damage  
Neointima formation may occur due to the damage to the protective endothelial 
cell layer lining the blood vessels (69-71). The damaged endothelial cells get 
activated in response to the injury and initiate an inflammatory response. The 
injury could be due to shear stress related to high blood pressure, 
ischemia/reperfusion injury or immunological injuries. Neointima formation is 
a complex and active process, in which cellular proliferation, cellular death, cell 
migration and deposition of extra cellular matrix occur simultaneously (10). 
The neointima consists of vascular smooth muscle cells, extra cellular matrix 
and inflammatory cells. The formation of neointima leads to decreased luminal 
patency and reduced blood supply, with subsequent ischemia in the end-organ. 
Neointima formation in the vessels of transplanted organs is a hallmark of CTD 
and a major component of long-term organ rejection. As noted above, there is 
no definitive treatment for CTD. Current standard immunosuppressive therapy 
with calcineurin inhibitors is successful in preventing or delaying short term 
rejection, however, CTD is not prevented (72). Moreover, long term 
administration of CNIs also have vasculotoxic effects (68,73). This indicates 
the need for additional treatment modalities in renal transplantation to protect 
against CTD. Since neointima clearly involves an inflammatory component, we 




studied the effects of oral nicotine on renal neointima formation in two different 
experimental models of progressive renal failure in chapter 6 of this thesis.  
 
Finally in chapter 7 the results of above studies are summarized and discussed. 
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Smoking in renal transplant recipients (RTR) is an acknowledged 
cardiovascular risk factor. It is however unclear whether smoking also increases 
the risk of graft failure (GF). In this study we prospectively assessed the 
association of current smoking versus past and never smoking with GF and 
mortality in 604 RTR (age 51.5 12.1 yrs, 55% male). At inclusion 133 (22%) 
were current smokers, 255 (42%) were past smokers and 216 (36%) never 
smoked. During follow up of 5.3 [4.7-5.7] yrs, 41 (7%) RTR experienced GF 
and 95 RTR (16%) died. Current smoking RTR had higher risk of GF 
compared to never smoking RTR (reference group) (Hazard Ratio (HR) = 3.3 
[95%CI] [1.5- 7.1], P=0.002). Past smoking RTR had similar risk of GF as 
never smoking RTR (HR=1.1 (0.5-2.6), P=0.7). Current smoking RTR and past 
smoking RTR were at higher risk for death than never smoking RTR (HR=2.1 
[1.1-3.8], P=0.016, and HR=2.4 [1.4-4.0], P=0.001 respectively).  
Smoking after renal transplantation is associated with risk for GF and mortality. 
Since past smoking is a risk factor for mortality but not for GF smoking 
cessation may be beneficial for RTR in delaying graft failure in long term. 
  






Cigarette smoking is an established risk factor for cardiovascular mortality and 
cancer (1). A detrimental role of smoking in kidney disease is now also 
emerging. In the general population, smoking is related to albuminuria and 
abnormal renal function (2). In prospective studies in patients with diabetes, it 
has been shown that smoking is a risk factor for development and progression 
of diabetic nephropathy to end-stage renal disease (3-5). Similar findings have 
been done in prospective studies in patients primary renal diseases, including 
lupus nephritis, autosomal polycystic kidney disease and IgA nephropathy, in 
which smoking was found to be a risk factor for decline of renal function and 
subsequent progression to end stage renal disease (6-8).  
It is, however, less clear whether active smoking is also risk factor for decline 
of renal function decline and graft failure (GF) after renal transplantation. Prior 
studies were retrospective in design and investigated pre-transplant cigarette 
smoking as a risk factor for development of graft failure after transplantation 
(9-11). To the best of our knowledge there are no prospective studies that have 
evaluated the effect of post-transplant smoking status on outcome in stable 
outpatient renal transplant recipients.  
We aimed to prospectively investigate whether post-transplant smoking is a risk 
factor for graft failure or mortality in renal transplant recipient recipients after 
transplantation.  
Patients and Methods 
Between August 2001 and July 2003 all outpatients renal transplant recipients 
(RTR) with a functioning graft for at least one year were asked to participate in 
a prospective cohort intended to study long-term graft survival. A total of 606 
renal transplant recipients signed written informed consent, from an eligible 
total of 847 (72% consent rate). The patients who consented were comparable 
to those who did not consent with respect to age, sex, body mass index (BMI), 
serum creatinine, creatinine clearance, and urinary albumin excretion (12). All 
participating subjects visited the outpatient clinic at least once a year, and 




serum creatinine was assessed at every visit. Continuous surveillance system of 
the outpatient program ensured up-to-date information on patient status. 
General practitioners or referring nephrologists were contacted in cases of 
missing data on patient status. Study details have previously been described 
more extensively (12-14). 
Further patient data for this study was obtained from the Groningen Renal 
Transplant Database. This database holds information on all renal 
transplantations performed at our center since 1968. 
The Institutional Review Board approved the study protocol (METc 2001/039). 
Funding sources neither had a role in the collection and analysis of data, nor in 
the publication of the manuscript.  
 
Endpoints 
Death-censored graft failure and patient mortality were chosen as primary 
endpoints. Death-censored graft failure was defined as return to dialysis or re-
transplantation. Mortality and graft failure of all RTR was recorded until 
August 2007. There was no loss to follow-up.  
 
Smoking status 
Smoking status was obtained by self-report (questionnaire) at inclusion date. 
Recipients gave details about their smoking habits, numbers of cigarette 
smoked and duration of smoking and time of smoking cessation. Smoking 
status was reported in by 604 of 606 RTR, which were all included in the 
present analysis. RTR were subdivided into three categories based on the 
smoking status: never smokers, current smokers and past smokers. Current 
smokers were those who reported smoking at the time of inclusion (regardless 
of intensity), past smokers were those who were non-smokers at the time of 
inclusion but had ever smoked in their life (regardless of duration or time of 
smoking cessation).  
 
 





Renal transplant characteristics  
Patient characteristics at time of inclusion were obtained from the Groningen 
Renal Transplant Database. These characteristics were recipients demographics 
(age, sex, follow-up at time of inclusion, time on dialysis prior to renal 
transplantation), donor demographics (age, sex, living/ postmortem), body 
composition (BMI, waist-circumference, body surface area (BSA)), clinical 
parameters (systolic and diastolic blood pressure, mean arterial pressure 
(MAP)) immunosuppressive regimen, use of antihypertensive medication, 
cardiovascular history, laboratory parameters (hemoglobin levels, CRP, 
albumin, glucose homeostasis, lipids) and renal function (serum creatinine, 
creatinine clearance, eGFR and albumin excretion rate). All measurements were 
described previously (12-14).  
 
Statistical analysis 
Data were analyzed with SPSS version 14.0 (SPSS Inc. Chicago, IL), and 
GraphPad Prism version 4.03 (GraphPad Software Inc. San Diego, CA). 
Normally distributed variables are given as means ± standard deviation, 
whereas variables with a skewed distribution are given as median [interquartile 
range]. Differences between the smoking groups were tested for statistical 
significance with one-way ANOVA for normally distributed variables, with 
Kruskal-Wallis test for skewed distribution, and with Chi-square test for 
categorical variables. To assess change in renal function over time, baseline 
renal function was related to information on renal function obtained at the 
outpatient clinic until 4 years after baseline. Follow-up date for patients who 
died with a functioning graft (n = 32) before this time was defined as renal 
function at the last visit to the outpatient clinic before death, and follow-up for 
patients with graft failure was defined as renal function at the last visit to the 
outpatient clinic before starting dialysis. For analyses with graft failure and 
mortality as outcome, survival analyses were performed according to Kaplan-
Meier and compared by overall log-rank tests. Further survival analyses, in 
which was adjusted for potential confounders was performed using Cox 




proportional hazard regression. Since smoking is an exposure it is inappropriate 
to adjust for variables that may be in the causal pathway between smoking and 
outcomes (15). To avoid over-adjustment by adjustment for variables that are 
intermediates between smoking and outcomes (15), we made a careful selection 
of variables that are unlikely to be intermediates between smoking and 
outcomes, but could confound the association by being associated with both 
smoking and outcomes. These variables are age, sex and time since 
transplantation. Although creatinine clearance and proteinuria may be in the 
causal pathway, we also considered it important to adjust for these variables, 
particularly for graft failure as end-point, because baseline values may 
importantly determine outcome. Proportionality assumptions were tested using 
Schoenfeld tests and log-minus-log survival plots. A two-sided P-value less 
than P<0.05 indicated statistical significance.  
 
Results 
Smoking data were available in 604 RTR with a mean (SD) age of 51.5 (12.1) 
years. Time of inclusion was at a median [interquartile range] of 6.0 [2.6-11.5] 
years post-transplantation. At the time of inclusion, 216 (36%) RTR had never 
smoked, 255 (42%) smoked in the past, and 133 (22%) were current smokers. 
Baseline characteristics according to smoking status are shown in table 1. Past 
smokers were significantly older than current smokers and never smokers. Past 
smokers were also more frequently men than never smokers, with current 
smokers in between. Similar trends and significant differences were present for 
history of myocardial infarction, waist circumference and statin use, while C- 
reactive protein was lowest in past smokers. Prednisolone dose and serum 












Table 1 Baseline characteristics subdivided according to the smoking status. 
 Smoking status  
p-value 
Non Smoker Past Smoker 
Current 
Smoker 
N (%) 216 (36) 255 (42) 133 (22)  
Recipient demographics     
Age, yrs 50±14 53±11 50±12 0.007 
Sex- Men, n (%)  102 (47) 156 (61) 73 (55) 0.01 





Dialysis time, months 27 [14-52] 28 [12-49] 25 [14-43] 0.5 
Duration of follow-up, yrs 5.3 [4.7-5.7] 5.2 [4.5-5.7] 5.2 [4.2-5.8] 0.29 
CVD history     
Myocardial infarction, n (%) 11 (5) 27 (11) 10 (8) 0.08 
TIA / CVA, n (%) 9 (4) 17 (7) 7 (5) 0.5 
Body composition     
       Body mass index, kg/m2 26±5 26±4 26±4 0.3 
       Waist circumference, cm 96±14 99±14 96±13 0.1 
Waist circumference - Men, 
cm  
96±12 102±12 99±13 0.001 
Waist circumference - 
Women, cm 
97±15 93±14 92±12 0.06 
Blood pressure     
Systolic pressure, mmHg 151±21 154±23 154±25 0.5 
Diastolic pressure, mmHg 90±10 90±10 90±10 0.7 
Mean arterial pressure mmHg 140±15 141±16 141±16 0.5 
Anti-hypertensive drugs, n (%) 184 (85) 226 (89) 118 (89) 0.5 
       ACE or AT II inhibitors, n 
(%) 
67 (31) 95 (37) 39 (29) 0.2 
        Anti hypertensive drugs 2 [1-3] 2 [1-3] 2 [1-3] 0.08 
Glucose homeostasis     







Glucose, mmol/l 4.6 [4.1-5.0] 4.5 [4.1-5.0] 4.6 [4.2-5.0] 0.6 
HOMA 2.4 [1.6-3.9] 2.3 [1.6-3.3] 2.0 [1.5-3.4] 0.1 




Diabetes, n (%) 45 (21) 46 (18) 16 (12) 0.1 
Lipids     
Total cholesterol, mmol/l 6±1 6±1 6±1 0.3 
LDL cholesterol, mmol/l 4±1 4±1 4±1 0.8 
Statin use, n (%) 100 (46) 140 (55) 60 (45) 0.09 
CRP, mg/l 2.0 [0.8-4.2] 1.9 [0.7-4.0] 3.4 [1.0-7.8] 0.01 
Albumin, g/dl 4±3 4±4 4±3 0.9 
Hemoglobin, mmol/l 
Anti rejection medications 
8.5 [7.9-9.1] 8.6 [8.1-9.2] 8.7 [8.1-9.5] 0.1 
Immunosuppressant     
Calcineurin inhibitor, n (%) 172 (80) 203 (80) 99 (74) 0.4 
Prednisolone dose, (mg/day) 10 [7.5-10] 10 [7.5-10] 10 [10-10] 0.01 
Proliferation inhibitor     
Azathioprine, n (%) 82 (38) 71 (28) 44 (33) 
0.9 
Mycophenolate mefotil, n (%) 76 (35) 113 (44) 60 (45) 
Donor demographics     
Age, yrs 36±15 38±15 37±16 0.6 
Sex - Men, n (%) 115 (54) 139 (55) 72 (55) 0.9 
Living kidney donor, n (%) 22 (10) 42 (17) 19 (14) 
0.14 
Postmortem donor, n(%) 194 (90) 213 (84) 114 (86) 
Renal function     
CrCl at inclusion, ml/min 66 [53-79] 64 [53-78] 64 [47-76] 0.4 
      Serum creatinine, 
(µmol/L) 





Proteinuria ≥0.5 g/24hr, n (%) 54 (25) 68 (27) 46 (35) 0.1 
 Normally distributed variables are presented as mean ± SD and differences were tested with 
one way analysis of variance. Variables with a skewed distribution as presented as median (25-
75 percentiles) and differences were tested with Kruskal-Wallis test. Categorical variables are 
presented as number (column percentage) and differences were tested with chi-square test.  
 
Abbreviations: 1. TIA: Transient ischemic attack, 2. CVA: Cereberovascular accident, 3. ACE: 
Angiotensin converting enzyme 4. ATII: Angiotensin II receptor, 5. HOMA: Homeostasis 
model assessment, 6. LDL: Low density lipoprotein, 7. CRP: C-reactive protein, 8. CrCl: 
Creatinine clearance, 9. GFR: Glomerular filtration rate. 
 






During the first 4 years of follow-up, decline in renal function was faster in 
current smokers than in past or never smokers (-4.2 (0.54) ml/min/yr vs. -1.9 






Figure 1 Decline in 











During follow-up for 5.3 [4.7-5.7] years, incidence of graft failure was higher 
in the group of current smokers than in the groups of past and non-smokers (19 
(14%) vs. 13 (5%) and 10 (4%) resp., figure 2A, p<0.001). Mortality was 
higher both in the groups of current and past smokers than in the group of non-
smokers (24 (18%) and 52 (20%) vs. 19 (9%), figure 2B, p<0.005).  
 


























Figure 2A Kaplan Meier analyses for death censored graft survival in renal transplant recipients 




Figure 2B Kaplan Meier analyses for mortality renal transplant recipients subdivided into 
current, past and never smoking 





In further cox-regression analyses, the associations of current smoking with 
graft failure and of current and past smoking with mortality remained 
independent of age, sex, baseline creatinine clearance and baseline proteinuria 
(table 2).  
 
Table 2 
  Never  Past  Current 
  HR (reference)  HR [95% CI] P  HR [95% CI]    P 
Graft failure        
 Model 1 1.0  1.1 [0.5-2.6] 0.7  3.3 [1.5-7.1] 0.002 
 Model 2 1.0  1.2 [0.5-2.7] 0.7  3.2 [1.5-7.0] 0.003 
 Model 3 1.0  1.6 [0.7-4.1] 0.3  3.3 [1.5-7.2] 0.003 
 Model 4 1.0  1.6 [0.6-3.8] 0.3  2.4 [1.1-5.6] 0.03 
Mortality        
 Model 1 1.0  2.4 [1.4-4.0] 0.001  2.1 [1.1-3.8] 0.02 
 Model 2 1.0  2.4 [1.4-4.0] 0.002  2.5 [1.3-4.5] 0.004 
 Model 3 1.0  2.2 [1.3-3.8] 0.004  2.1 [1.1-3.8] 0.02 
 Model 4 1.0  2.2 [1.3-3.8] 0.004  2.0 [1.1-3.7] 0.03 
Table 2. Univariate and multivariate analyses of past and current smoking as risk factors for 
graft failure and mortality. 
 
Model 1: Crude 
Model 2: Model 1 + recipient age, gender and time since transplantation. 
Model 3: Model 2 + creatinine clearance. 
Model 4: Model 3 + proteinuria. 
  





In this study, we found that active smoking is associated with a relatively fast 
decline of renal function after transplantation, translating into it being an 
independent risk factor for development of graft failure after renal 
transplantation. We also found that current smoking and past smoking both are 
independent risk factors for mortality after transplantation.  
 
We also found that 22% of our large, stable outpatient RTR population were 
current smokers and 42% were past-smokers. Data on smoking habits post-
transplantation are scarce. In the ALERT trial, with baseline measurements in 
1996-1997, prevalence of current smokers among outpatient RTR beyond 6 
months after transplantation was reported to be 18.9% (16). No data on past 
smoking were presented. In a more recent cross-sectional study among RTR in 
Germany, 12.5% were current smokers and 46.5% were past smokers (17). So, 
the prevalence of current smokers in our study was relatively high and the 
percentage of past smokers was relatively low compared to other studies. 
Possibly, stimulation of quitting smoking after transplantation was less well-
established in our clinic than in the other clinics at the time baseline 
measurements were performed.  
 
To the best of our knowledge our study is the first to prospectively assess 
potential association of post-transplant assessment of smoking status with 
development of graft failure and mortality after transplantation. This is 
important, because it has been estimated that shortly after transplantation 
approximately 30% of patients that smoke while being pre-transplant, quit 
smoking after transplantation (17) . Prior studies were retrospective in design or 
investigated pre-transplant cigarette smoking as a risk factor for development of 
graft failure and mortality after transplantation (9-11). In a substudy of the 
ALERT trial, the only other study to the best of our knowledge to date that 
assessed the association between post-transplant smoking status and outcome, it 
was found that current smoking as compared to current non-smoking was a risk 





factor for graft failure without inclusion of death in the end-point, with a hazard 
ratio of 2.29, which dropped to 1.77 when death was added to the combined 
end-point (18). This implies that current smoking as compared to current non-
smoking was a less strong risk factor for death than for graft failure in this trial 
(18). If we take our data into account, it seems very important to make the 
distinction between past-smoking and never smoking among current non-
smokers, because never smokers have the lowest risk, while in the ALERT trial 
past-smokers were in the control group, which may have given an 
underestimation of the actual risk held by current smoking. The mechanism 
underlying the association between current smoking and graft failure cannot be 
established in our data or that of the ALERT trial. Interestingly, however, we 
found that past smoking is a risk factor for mortality but not for graft failure, 
which suggests that atherosclerosis of the native vasculature plays no – or a 
minor – role in the association between smoking and graft failure in RTR. A 
role for the intra-renal vasculature has been suggested in a cross-sectional study 
of 279 renal transplant biopsies, where it was found that severity of vascular 
intimal fibrous thickening was associated with current smoking, whereas the 
degree of arteriolar hyalinosis and chronic sclerosing nephropathy were 
associated with time since transplantation (19). Thus, a vascular effect of 
current smoking seems to prevail, even in transplanted kidneys. In line with this 
is the finding that post transplant smoking has been found to a risk factor of 
coronary artery disease (CAD) in heart transplant patients (20;21).  
 
Strengths of our study are its prospective design, its collection of data not only 
on current smoking, but also on past and never smoking and the large size of 
the population. There are also several limitations to the study. First, all the data 
on smoking status are self reported and based on a questionnaire that was 
applied once at the baseline of the study, so we have no data on smoking status 
of recipients and donors before transplantation or on change in smoking status 
beyond baseline of the study. However, any un-assessed change in smoking 
status beyond the baseline of our study may only result in weakening of 




otherwise stronger associations. So, the associations that we found are at worst 
an underestimation of truly existing associations. Second, the relatively late 
(median 6 years post-transplant) time of inclusion may have imparted a survival 
bias on those included in the study, as smokers may already lost their graft or 
died before the time of the study recruitment. However, inclusion of patients as 
they are appearing at an outpatient clinic gives a picture of actual clinical, 
which is may less well be the case when subjects are included at a certain time 
point after transplantation. Third, our study was too small to allow for 
meaningful analyses of dose-effect relationships of intensity of smoking or 
degree of total exposure. It would be interesting if future studies in larger 
databases or combinations of databases could address this issue.  
 
In conclusion, current smoking poses RTR at increased risk for graft failure and 
mortality. Past smoking is a risk factor for mortality but not for graft failure, 
suggesting atherosclerosis of the native vasculature to play no important role in 
the association between smoking and graft failure in RTR. Stop smoking could 
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Chronic kidney disease (CKD) is a common complication after lung 
transplantation (LTx). Smoking is a risk factor for many diseases, including 
chronic kidney disease (CKD). Smoking cessation for >6 months is required for 
LTx-enlistment. However, the impact of smoking history on CKD development 
after LTx remains unclear. We investigated the effect of former smoking on 
CKD and mortality after LTx. CKD was based on glomerular filtration rate 
(GFR) (
125
I-iothalamate-measurements). GFR was measured before and 
repeatedly after LTx. 134 patients never smoked and 192 previously smoked 
for a median of 17.5 pack years. At 5 yrs after LTx, overall cumulative 
incidences of CKD-III, CKD-IV and death were 68.5, 16.3 and 34.6%, 
respectively. Compared to never smokers, former smokers had a higher risk for 
CKD stages III (HR [95%CI]=1.69 [1.27-2.24]) and IV (HR=1.90 [1.11-3.27]), 
but not for mortality (HR=0.99[0.71-1.38]). Adjustment for potential 
confounders did not change results. Thus, despite cessation, smoking history 
remained a risk factor for CKD in LTx recipients. Considering the increasing 
acceptance for LTx of older recipients with lower baseline renal function and an 
extensive smoking history, our data suggest that the problem of post-LTx CKD 
may increase in the future. 






Chronic kidney disease (CKD) is a serious complication after lung 
transplantation (LTx). In most LTx-recipients renal function deteriorates 
progressively, often resulting in CKD (1). Progression from CKD to end-stage 
renal disease (ESRD) currently develops in between 3-10% of LTx recipients 
(2-4). Recipient age and life-expectancy after LTx are increasing, so it is likely 
that the a priori risk for CKD after LTx is increasing concomitantly, with 
possible consequences for the number of LTx recipients that develop ESRD on 
the long term (5). 
Approximately 60% of LTx recipients have a history of smoking (6). This is the 
highest rate reported among recipients of solid organs: former smokers account 
for 51-54% of renal-transplant recipients (7,8), 42-50% of liver-transplant 
recipients (9), and 45% of heart-transplant recipients (5). Moreover, many 
former smokers amongst LTx recipients smoked heavily, as around 40-45% of 
them undergo LTx because of end-stage pulmonary emphysema, which is 
largely attributable to heavy smoking (6). Pulmonary emphysema, 
cardiovascular disease and lung cancer are well-known complications of 
smoking (10-12). It may be less well-known that smoking is also a risk factor 
for CKD (13,14). We wondered whether, even after smoking-cessation, 
smoking history could be relevant for morbidity after LTx, in particular CKD, 
because of the high prevalence of both CKD and former smoking in LTx 
recipients. 
Transplant centers, including our own, commonly require that patients have 
stopped smoking for at least six months before being enlisted for LTx (15,16). 
In the current study, we analyzed the potential association between smoking 
history before LTx and development of CKD after LTx in a large single center 
cohort of LTx recipients. In addition, we analyzed the impact of past smoking 








Patients and methods 
 
A total of 370 lung transplantations, of which 22 heart-lung transplantations 
were performed at the University Medical Center of Groningen (UMCG), the 
Netherlands between 1990 and 2008. Pediatric transplantations (n=17) and re-
transplantations (n=13) were excluded. Quantitative data on smoking history 
were obtained from patient records. We excluded , 14 patients of the remaining 
340 patients from further analyses because of lack of data on smoking history, 
leaving a total of 326 patients eligible for evaluation. Further clinical 
information of all individuals was gathered at baseline and during follow-up. 




Smoking cessation for at least 6 months is a requirement for LTx enlistment. 
Returning to active smoking after LTx is very strongly disapproved and occurs, 
to the best of our knowledge, only exceptionally. Smoking history prior to 
transplantation was quantified by number of pack years. One pack year is 
defined as 20 cigarettes (one pack) smoked per day for one year. Patients were 
categorized into never and former smokers and the latter were further 




Glomerular filtration rate (GFR) measurements were performed
 
by constant 




I-Hippuran as described 
before (17-19). This method is considered a gold standard method for GFR 
measurement, has a day-to-day coefficient of variation of 2.5 % (19) and is 
used for the development and validation of novel renal function equations (20). 
Height and weight were measured in every patient before every GFR 
measurement. Body surface area (BSA) was calculated as 









(21), and GFR was expressed per 1.73 m
2
 of 
BSA. GFR measurements were performed routinely at out-patient basis, before 
transplantation and at regular time-intervals after transplantation. 
 
Endpoints of the study 
Primary endpoints of the study were CKD-III and CKD-IV. CKD-III and CKD-
IV were defined as GFR<60 ml/min/1.73m
2
, and GFR<30 ml/min/1.73m
2
 
respectively, according to the cut-off values in the NKF K/DOQI guidelines 
(22). 
We used GFR measurements by radiolabelled Iothalamate for the definition of 
CKD because in LTx recipients creatinine-based GFR estimations are biased by 
the large variation in muscle mass (23). For the primary analyses, definition of 
CKD was based on the first GFR measurement below the cut-off values 
defining the stages of CKD. We did this because beyond 2 years after LTx we 
measured GFR with 2-year intervals. Consequently, a proportion of patients 
with one measurement below the CKD-threshold lacked follow-up until a 
confirmatory measurement. Defining CKD based on at least 2 measurements 
below the CKD-threshold would result in underestimation of true cumulative 
incidence of CKD. Moreover, in patients that had a GFR measurement below 
the cut-off, only 2.4% the second GFR measurement was inconsistent with the 
former measurement. This assured us that use of this definition for endpoints 
was appropriate. However, to consent with the NKF K/DOQI guidelines CKD 
should be confirmed by a second measurement >90 days later, we performed 
secondary analyses with the endpoints defined as such. We furthermore 
performed a secondary analysis with doubling of serum creatinine (DSC) as 
alternative renal endpoint to check consistency across renal endpoints. DSC 
was defined as a doubling of serum creatinine, confirmed by a similar value 
>90 days after the initial doubling. 
ESRD was defined as the requirement of renal replacement therapy. We 
recorded occurrence of ESRD and death until January 2010. Causes of death 
were coded according to the international Classification of Diseases (ICD-9).  






Immunosuppressive protocols used over time are described in more detail 
elsewhere (24). In short, maintenance immunosuppression consists of a 
calcineurin inhibitor (CNI) based immunosuppressive regimen, combined with 
steroids and azathioprine (Immuran; GlaxoSmithKline,United Kingdom). 
Cyclosporine (Neoral; Novartis,Switzerland) was the CNI used until 2001. The 
targeted whole blood trough level of CsA was initially 400 µg/L, tapering to 
150 µg/L within the first three weeks. Tacrolimus (Prograft; Astellas,The 
Netherlands) was the CNI used from 2001 onwards. Between 2001-2004 target 
trough levels were 20 µg/L during the first three weeks, 15 µg/L until the third 
month and 10-12 µg/l thereafter. Lower peri-operative tacrolimus trough levels 
were targeted from 2004: 15-18 µg/L during the first three weeks, 12-15 µg/L 
until the third month, and 10-12 µg/L thereafter. We further decreased target 
levels to 8-10 µg/L in the case of EBV-reactivation (24). Prednisolone dose was 
0.2mg/kg/d until the third month and 0.1 mg/kg/d thereafter. Azathioprine dose 
was 1.5-3 mg/kg/d. Induction consisted of ATG (Thymoglobulin; Pasteur-
Merieux,France) until 2001 and Basiliximab induction thereafter (Simulect; 
Novartis,Switzerland). We switched some patients from Azathioprine to 
Mycophenolate Mofetil (Cellcept; Roche,Switzerland). Patients received 
P.Jeroveci prophylaxis, Herpes prophylaxis and CMV-prophylaxis (at-risk 
patients only, from 2001 onwards).  
 
Statistical analysis 
Data were analyzed with SPSS version 18.0, STATA version 11.2 and R 
version 2.12.0. The data were obtained from preexistent databases and from 
patient chart review. Categorical variables are reported as frequencies and 
percentages. Variables with normal distribution are presented as mean with 
standard deviation (SD) and variables with a skewed distribution are presented 
as median with interquartile range [IQR].  





Recipient characteristics are shown according to categories of smoking habits 
prior to transplantation. We divided patients into never smokers and former 
smokers and subdivided the latter category into three categories according to 
number of pack years. Differences between groups were tested by one-way 
ANOVA for linear effects for continuous variables and Chi Squared-test for 
categorical variables. We performed adjustment for multiple comparisons over 
time using Bonferroni correction.  
CKD-III, CKD-IV and all-cause mortality were endpoints in this study. 
Cumulative incidences of CKD-III and CKD-IV were calculated for never 
smokers and groups of former smokers using competing risk analysis. 
Differences between smoking exposure groups were tested with Gray’s test for 
competing risks data (25,26). We calculated population attributable risk as 
(proportion exposed*((adjusted hazard ratio-1)/adjusted hazard ratio)*100% 
(27). The association of former smoking with CKD-III and IV was modeled 
with Cox cause-specific hazards regression (28) and the association with 
mortality with standard Cox proportional hazards regression. Variables that we 
selected as covariates in multivariate analyses were patient demographics, 
variables that were different between the smoking exposure groups at baseline 
and variables previously found to be risk factors with renal risk after LTx 
(29,30). Linearity of continuous covariates was assessed using multivariable 
fractional polynomials in R. According to this package optimal model-fit for 
GFR would be obtained by a 1000/GFR transformation, whereas age, BMI and 
pack years were either best fitted in a linear non-transformed way or did not 
contribute to the model. We therefore used a 1000/GFR-transformation of GFR 
in the analyses. To assess dose-dependency, the number of pack years was 
analyzed as continuous variable. We performed secondary analyses without the 
never smokers and stratified for age (< 47 and > 47 years, population median) 
and for diagnosis (COPD vs. non-COPD) to rule out that (dose) effects were 
solely based on the differences in characteristics of never smokers and former 
smokers. Moreover, in further secondary analyses, we repeated the multivariate 
analyses with CKD-III and CKD-IV confirmed by a second measurement >90 




days later and with doubling of serum creatinine, also confirmed by a second 
measurement >90 days later as alternative renal endpoints. Lastly, as body 
dimensions may change substantially after LTx we performed a secondary 
analysis with body-surface-area as time-dependent variable. Possible 
interactions between variables were also assessed. Hazard ratios (HR) are 
reported with 95% confidence interval [95%CI]. Final results were considered 




Quantitative data on previous history of smoking were available in 326 (96%) 
patients: 134 (41.1%) patients had never smoked and 192 (58.9%) patients had 
smoked a median [IQR] of 17.5 [10-30] pack years. Baseline characteristics of 
never smokers and former smokers stratified for number of pack years are 






smokers       
Former 
smokers        
   0 Pack years  
1-10  
Pack years  
11-25 
Pack years  
>25  
Pack years  P-value 
Number of patients  134  62  74  56   
Pack years   0 ± 0  6.5 ± 3.0  18.1 ± 4.7  38.7 ± 12.1   
Male Sex (n, %)  73 (54.3)  26 (41.9)  40 (54.1)  27 (48.2)  0.37 
Recipient age* (years)  36.8 ± 12.5  48.5 ± 8.2  50.7 ± 6.9  55.1 ± 5.6  <0.001 
Race           0.88 
    Whites  131 (99.3)  62 (100)  73 (98.6)  56 (100)   
    Blacks  3 (0.7)  0 (0)  1 (1.4)  0 (0)   
Glomerular filtration rate 
(ml/min/1.73m2)  108 ± 26  98 ± 18  101 ± 15  93 ± 17  0.04 
Pre-transplantation SCr 
(μmol/L)  77 ± 19  80 ± 18  79 ± 15  79 ± 16  0.68 
Body mass index (BMI) 
(kg/m²)  21.0 ± 3.5  22.1 ± 3.6  23.3 ± 4.0  23.2 ± 3.2  <0.001 
Hypertension (n, %)  26 (19.5)  15 (24.2)  13 (17.6)  8 (14.3)  0.59 





Diabetes Mellitus (n, %)  23 (17.3)  2 (3.2)  4 (5.4)  2 (3.6)  0.002 
Pulmonary diagnosis (n, %)          <0.001 
    COPD  4 (3.0)  10 (16.1)  25 (33.8)  39 (69.6)   
    α1-antitrypsin-deficiency 
(AAT)  2 (1.5)  23 (37.1)  31 (41.9)  10 (17.9)   
    Cystic Fibrosis (CF)  61 (45.5)  3 (4.8)  1 (1.4)  0 (0)   
    Pulmonary Hypertension 
(PH)  20 (14.9)  9 (14.6)  4 (5.4)  3 (5.4)   
    Pulmonary Fibrosis (PF)  28 (20.9)  12 (19.4)  10 (13.5)  4 (7.1)   
    Other  19 (14.1)  5 (8.1)  3 (4.1)  0 (0)   
Type of transplantation (n, %)          <0.001 
    Unilateral  21 (15.7)  14 (22.6)  15 (20.3)  19 (33.9)   
    Bilateral   100 (74.6)  46 (74.2)  57 (77.0)  36 (64.3)   
    Combined organ  13 (9.7)  2 (3.2)  2 (2.7)  1 (1.8)   
Immunosuppressive regimen 
(n, %)          0.045 
    CsA-based  57 (42.5)  35 (56.5)  39 (52.7)  16 (28.6)   
    Tac-based  77 (57.5)  27 (43.5)  35 (47.3)  40 (71.4)   
Transplant series (n, %)          0.043 
    1990-1996  23 (17.2)  10 (16.1)  10 (13.5)  5 (8.9)   
    1997-2000  34 (25.4)  24 (38.7)  24 (32.4)  11 (19.6)   
    2001-2004  37 (27.6)  16 (25.8)  15 (20.3)  12 (21.4)   
    2005-2008  40 (29.9)  12 (29.7)  22 (29.7)  28 (50)     
 
* Recipient age at time of transplantation. sCr: serum creatinine, COPD: Chronic obstructive 
pulmonary disease, CsA: cyclosporin, Tac: Tacrolimus. Differences between groups were tested 
by one-way ANOVA for linear effects. 
 
Overall, the former smokers were older, had higher BMI, more often had 
pulmonary diagnoses chronic obstructive pulmonary disease (COPD) or α1-
antitrypsine-deficiency, (as opposed to cystic fibrosis, pulmonary fibrosis or 
pulmonary hypertension in never smokers), more often underwent unilateral 
lung transplantation and had lower GFR before transplantation. Comparing 
subgroups of former smokers the patients with higher numbers of pack years 
were found to be older, were more often transplanted for COPD and more often 
received Tacrolimus-based maintenance immunosuppression. A relatively large 
proportion of heavy former smokers was transplanted in the most recent 
stratum. This reflects recent changes in acceptance policy for LTx enlistment. 




Other characteristics were similar for the smoking exposure groups. 
Cyclosporine and Tacrolimus trough levels were similar for never smokers and 
all groups of former smokers in all time-intervals during follow-up after 











months  N 
Never 
smokers 0 Pack years 
293 ± 











43 37 180 ± 25 31 175 ± 34 28 165 ± 45 25 
 >25 Pack years 
280 ± 
35 16 180 ± 28 16 172 ± 22 15 172 ±17 10 
Tacrolimus 
(ng/mL)          
Never 



















1.9 32 10.7 ± 2.3 31 10.0 ± 1.8 18 




1.7 29 10.3 ± 1.5 28 9.8 ± 1.2 20 
 
P > 0.05 for Cyclosporin and Tacrolimus trough levels in never smokers and groups of former 
smokers at all-time intervals after lung transplantation. Differences between groups were tested 
by one-way ANOVA for linear effects.  
 
Mean baseline GFR was 102±22 ml/min/1.73m
2
. Baseline GFR was higher in 
never smokers than in former smokers, but this difference did not persist after 
adjustment of GFR for recipient age. Renal function declined considerably after 
LTx, on average -43±24% within 2 years after LTx. The decline was 
particularly steep in the first 6 months after LTx, slowly leveling off beyond 12 
months after LTx (figure 1). The slope of GFR decline in the first year after 
LTx was steeper in former smokers than in never smokers (-34±20 and -
25±18% resp., P=0.005). Former smokers generally had a significantly lower 





mean GFR than never smokers from 6 months after LTx onwards. The former 


























Means with standard error of GFR relative to body-surface-area per group according to groups 
based on number of pack years (0 Pack years, 1-10 Pack years, 11-25 Pack years, >25 Pack 
years). Differences between groups were tested by one-way ANOVA for linear effects. 
§P<0.05, NS after Bonferroni correction, *P<0.006, significant after Bonferroni correction # 
Mean estimates not reported for <10 patients. 




The overall cumulative incidence of CKD-III at 5 years after LTx, taking 
competing risk of death into account, was 68.5%, with a cumulative incidence 
of 58.2% in never smokers vs. 74.4% in former smokers (P<0.001). This 
cumulative incidence was 72.6%, 74.7% and 75.8% (P<0.001) in former 
smokers with a history of 1-10, 11-25 and >25 pack years of smoking, 
respectively. The overall cumulative incidence of CKD-IV at 5 years after LTx, 
taking competing risk of death into account, was 16.3% with a cumulative 
incidence of 10.7% in never smokers vs. 20.2% in former smokers (P=0.004). 
This cumulative incidence of CKD-IV at 5 years after LTx was 15.0%, 20.4% 
and 26.9% (P=0.004) in former smokers with a history of 1-10, 11-25 and >25 
pack years of smoking, respectively.  
Fifteen (5% of total) patients (mean age at LTx 38±13 years) progressed to 
ESRD at a mean follow-up of 7.2±4.1 years. Of those patients, 7 had COPD 
and 7 had cystic fibrosis. Current average follow-up of patients alive is 5.3±4.2 
years; hence the proportion of ESRD might increase with longer follow-up. We 
refrained from further (multivariate) analyses on determinants of ESRD, 
because of the small number of patients with ESRD. 
 
In univariate Cox proportional Hazard analyses, former smokers had an 
increased risk of CKD-III (HR [95%Confidence Interval(CI)]=1.69 [1.27–
2.24], P=0.001) and CKD-IV (HR=1.90 1.11-3.27], P=0.02) compared to never 
smokers. Among the former smokers, there was an increase in risk of CKD-III 
per group according to number of pack years, with HRs of 1.57 [1.09-2.25], 
P=0.015, 1.65 [1.15-2.36], P=0.006 and 1.92 [1.32-2.79], P=0.001 for patients 
with a history of 1-10, 11-25 and >25 pack years of smoking respectively, 
compared to never smokers. The same was true for CKD-IV, with HRs of 1.30 
[0.63-2.70], P=0.48, 1.96 [1.04-3.71], P=0.04 and 2.78 [1.41-5.46], P=0.003 for 













Cumulative incidences of CKD-III (left, (P<0.001)) and CKD-IV (right, (P<0.001)) according 
to groups based on number of pack years (0 Pack years, 1-10 Pack years, 11-25 Pack years, >25 
Pack years). Differences between groups were tested with grays test for competing risks data. 









In analyses with pack years of smoking as a continuous variable, the HRs per 
10 pack years of smoking for CKD-III and-IV were 1.19 [1.09–1.28], P<0.001 
and 1.40 [1.20-1.62], P<0.001 (table 3). In the multivariate analyses this dose-
dependent relation remained significant for both CKD-III (HR 1.25 [1.10–
1.42], P<0.001) and CKD-IV (HR 1.46 [1.17–1.83], P<0.001) (table 3). The 
corresponding adjusted population attributable risks of former smoking (i.e. the 
CKD-rate reduction if all patients would have been never smokers) were 11.8% 
for CKD-III and 18.6% for CKD-IV. 
 
In secondary analyses, the dose-dependent increase in renal risk persisted after 
exclusion of the never smokers from the analysis (table 4). Results of the 
analyses stratification by age (<47 and >47 years, population median) and 
diagnosis (COPD vs. non-COPD) are also displayed in table 4. As can be seen, 
hazard ratios were relatively high in patients < 47 years and in patients with 
diagnoses other than COPD. To investigate whether the risk was different 
between stratification groups, we tested for interaction between strata and pack 
years in the fully adjusted model. There was no significant interaction between 
age-strata and pack years for CKD stage III (P=0.92) and CKD stage IV 
(P=0.81). For diagnosis strata, there was a trend towards interaction for CKD 
stage III (P=0.18) and significant interaction for CKD stage IV (P=0.04). These 
data are consistent with pack years of smoking being a risk factor for CKD both 
in patients with COPD and patients without COPD, but highest risk in patients 
without COPD as primary diagnosis. As a total the results are consistent and 













  CKD stage III   CKD stage IV  
Secondary Analysis   HR [95%CI] P-value   HR [95%CI] P-value 
       
Stratified by age       
  < 47 years Pack years* 1.30 [0.88-1.93] 0.19  2.31 [1.01-5.32] 0.05 
  > 47 years Pack years* 1.21 [1.05-1.40] 0.008  1.36 [1.07-1.72] 0.04 
Statified by diagnosis       
  COPD Pack years* 1.18 [1.02-1.38] 0.03  1.36 [1.07-1.72] 0.01 
  other than COPD Pack years* 1.50 [1.11-2.01] 0.008  2.20 [1.17-3.97] 0.01 
Former smokers only Pack years* 1.23 [1.06-1.42] 0.005  1.42 [1.11-1.81] 0.005 
 
* per 10 pack years 
All analyses are multivariate cause-specific hazards regression analyses for pack years and 
CKD-III (or greater) and CKD-IV (or greater) 
 
We found that if analyses were repeated with CKD confirmed by a second 
value overall, cumulative incidences of CKD-III and CKD-IV after 5 years of 
follow-up were lower, with cumulative incidences of 57.8 and 10.4% for CKD-
III and CKD IV respectively. The results of analyses of smoking as a risk factor 
for CKD remained essentially unchanged though, with HRs of 1.17 [1.03–
1.33], P=0.02 and 1.63 [1.25-2.13], P<0.001 per 10 pack years of smoking for 
CKD-III and CKD-IV respectively in the fully adjusted model. Likewise, 
former smoking was dose-dependently associated with doubling of serum 
creatinine as renal endpoint, with a HR of 1.28 [1.10-1.49], P=0.002 per 10 
pack years in the fully adjusted model. Lastly, we performed multivariate 
analyses with body-surface-area as a time-dependent variable, yielding HRs of 
1.22 [1.08-1.39], P=0.002 for CKD-III and 1.48 [1.18-1.85], P=0.001 CKD-IV.  
 
The overall cumulative incidence of all-cause mortality at 5 years after LTx was 
34.6%, with a cumulative incidence of 32.9% never smokers vs. 37.2% in 
former smokers (P=0.4). In univariate Cox-regression analysis, former 





smokers’ risk of mortality was similar to that of never smokers (HR = 0.99 
[0.71–1.38], P=0.9). We found that the main causes of death were graft failure 
(34.2%, after mean 3.8±3.4 years) and malignancy (17.1%, after a mean of 
5.0±4.0 years). Only a small proportion of patients died of cardiovascular 
causes (6.2%, after a mean of 4.6±4.6 years). Former smokers more often died 
of malignancy than never smokers (23% vs. 8.5% resp., P=0.03). There were no 
other significant differences in causes of death between former smokers and 
never smokers (Table 5). 
 
         
Cause of death  
Total  
N (%)  
Never 
smokers     N 
(%)  
Former 
smokers   N 
(%)  P-value 
         
Peri-operative death  17 (11.8)  8 (13.6)  11 (12.6)   
Multi-organ failure  12 (8.3)  8 (13.6)  4 (4.6)   
Infection  19 (13.2)  7 (11.9)  12 (13.8)   
Cardiovascular  9 (6.3)  2 (3.4)  7 (8.0)   
Malignancy  25 (17.4)  5 (8.5)  20 (23)  0.03 
Transplant failure  50 (34.7)  25 (42.4)  25 (28.7)   
Other   12 (8.3)   4 (6.8)   8 (9.2)     
 
Discussion  
This study shows for the first time that former smoking is associated with 
increased risk of CKD-III and CKD-IV after LTx. We found the increased risk 
of former smoking on CKD to be independent of potential confounders, 
including baseline GFR, recipient age and pulmonary diagnosis. The 
association between former smoking and CKD was further supported by 
evidence of dose-dependency.  
The difference in renal function between never and former smokers starts early 
after transplantation. Whereas both never smokers and former smokers had a 
steep initial decline in GFR, the initial decline in GFR was more pronounced in 
former smokers, and even more marked in former smokers with higher number 




of pack years. After the early rapid decrease in GFR, the rate of decline 
gradually leveled-off over time, but differences between groups clearly 
persisted.  
 
Our results suggest that former smoking primes the kidneys for accelerated 
decline in GFR after LTx. The renal susceptibility to accelerated decline in 
GFR was not accounted for by adjustment for pre-transplant GFR. 
Nevertheless, it remains possible that former smokers have pre-existent renal 
damage. This is not necessarily captured by GFR as kidneys are known to have 
a certain amount of reserve capacity. This allows kidneys to maintain GFR at a 
certain level by compensating for damage and/or nephron loss. Consequently, 
substantial renal damage can be present without any measurable effect on GFR. 
In addition, it has been demonstrated that intra-renal vascular pathology 
(myointimal hyperplasia, arteriolar hyalinosis, glomerular sclerosis) in renal 
biopsies of former smokers is more prominent than in never smokers without an 
apparent difference in renal function (31). Thus, renal damage related to prior 
smoking can be present in the kidney after smoking cessation without being 
reflected in GFR. Interestingly, it has been observed that renal histological 
lesions (including myointimal hyperplasia and arteriolar hyalinosis) amplify the 
nephrotoxic effects of CNIs in renal transplant recipients (32). Accordingly, 
renal vascular lesions induced by prior smoking might well be involved in our 
observations that former smokers are more susceptible to post-transplantation 
CKD, despite that they no longer smoke. Further research will need to clarify 
whether these suggested mechanisms indeed play a role in the accelerated 
decline of GFR in former smokers.  
Various mechanisms could underlie the persistence of smoking-associated 
damage after smoking cessation. Recently it was found that smoking-induced 
changes in epigenetics of blood platelets can persist for more than 10 years after 
smoking cessation, showing that distant effects of smoking can last for many 
years (33,34). These findings are corroborated by data of persisting increases in 
risk of smoking-associated conditions long after cessation of smoking, e.g. the 





risk of lung cancer remains increased 15-fold in men and 9-fold in women for 
at least ten years after smoking cessation (35).  
Our study is the first to identify former smoking as a risk factor for CKD in 
lung transplant recipients. The risk was not explained by clinical renal 
parameters, notwithstanding gold standard renal function measurements. This is 
of substantial clinical significance, as it means that reliable smoking history 
could aid in risk-assessment. In a general sense, the association between former 
smoking and the risk for CKD is very sparsely documented, and so far, data in 
populations with a high renal risk are lacking altogether.  
 
We did not observe any relationship between former smoking and mortality 
after LTx, although former smokers more frequently died of malignancy. This 
would be consistent with the increased risk of malignancy in smokers in the 
general population. In the general population, smoking is furthermore 
associated with cardiovascular disease. However, no association between 
former smoking and cardiovascular death was observed in this study. 
Importantly, the chances of finding an association between former smoking and 
cardiovascular disease were small because LTx recipients generally are 
relatively young and thoroughly screened on cardiovascular status prior to 
transplantation. They are therefore unlikely to develop cardiovascular disease 
within several years. Moreover, despite the development of cardiovascular risk 
factors due to the use of immunosuppressants (hypertension, hyperlipidemia, 
hyperglycemia etc.), LTx recipients are more likely to die of other 
transplantation-related causes (such as transplant failure or infection). This is 
supported by the high mortality due to transplant failure and low numbers of 
cardiovascular death in our population.  
 
Our study has several limitations. First, several differences in baseline 
characteristics existed between the never smokers and former smokers. The 
former smokers more often had pulmonary emphysema and were relatively old, 
whereas the never smokers often had cystic fibrosis, pulmonary fibrosis or 




pulmonary hypertension and were relatively young. To ensure that the results of 
our analyses were less likely to be confounded by these differences, we 
adjusted for recipient age, gender, baseline GFR, BMI, pulmonary diagnosis, 
type of transplantation, medication-regimen, hypertension, diabetes and 
transplantation year. We also performed several sensitivity analyses to check 
the consistency. Even so, the associations persisted.  
In secondary analyses we found that in patients with diagnoses other than 
COPD packyears of former smoking was associated with highest risk for CKD. 
It should be noted that this group contains relatively many younger patients and 
patients with cystic fibrosis, whom differ in many aspects from patients with 
COPD (e.g. glomerular hyperfiltration making kidneys more susceptible to 
CNI-toxicity, higher prevalence of diabetes after LTx, higher prevalence of 
chronic rejection, higher doses of immunosuppression after LTx, all risk factors 
for CKD). It is possible that the difference between diagnosis strata is due to 
residual confounding, however, it is also possible that this reflects a difference 
in susceptibility of kidneys to the noxious effects of former smoking between 
the diagnosis groups.  
In addition, it is hard to exclude that some patients have resumed smoking after 
LTx, despite very strong discouragement. Sobering data on smoking 
resumption after LTx have recently been published, showing that some 11% of 
patients had resumed smoking – without informing their doctors (15). 
Nevertheless, we believe it is unlikely that our conclusions are affected by an 
undetected subcohort that resumed smoking. First of all, others have reported 
much lower numbers of patients resuming smoking after LTx (16,36). Also, 
smoking resumption is more likely after an abstinence period of <6 months. 
Our center requires an abstinence period of at least 6 months before enlistment. 
Moreover, a random sample of patients from our population was recently tested 
for exhaled carbon monoxide levels and we found no evidence for smoking 
resumption. Last, whereas we cannot fully exclude smoking resumption in a 
minority of patients, it is unlikely that the presence of a small subcohort could 
lead to the clear dose-dependent effect of former smoking on CKD observed 





here in the whole cohort. Another limitation of the study is the lack of data on 
behavior, socio-economic status, presence of other co-morbid conditions and 
environmental factors. These parameters could be confounding the association 
between former smoking and CKD. While it would have been appropriate to 
adjust for these factors, such factors were not documented in the current study 
and could not be taken into account, resulting in potential unmeasured 
confounding.  
A major strength of our analysis is the use of 125I-Iothalamate GFR 
measurements for baseline and follow-up. This method is considered a gold 
standard method for GFR measurement and provides a very reliable 
measurement (18). This measurement is superior especially in populations such 
as LTx, where long-term changes in muscle-mass confound creatinine-based 
renal function estimates (23). A comparison of this method with the more 
widely available eGFR calculations was published in an early subgroup (N=40) 
from this cohort in 2000 (23), showing that renal function loss is 
underestimated by creatinine-derived renal function estimates in LTx recipients. 
Another strength of this study is the availability of serial calcineurin inhibitor 
trough levels in never smokers and groups of former smokers. These levels 
were similar for never smokers and former smokers, indicating similar CNI 
exposure and making confounding by CNI toxicity unlikely. Furthermore, this 
study shows data on a large cohort of LTx recipients with a good representation 
of all kinds of LTx recipients with long follow-up, without loss to follow-up.  
In conclusion, the number of pack years of prior cigarette smoking was dose-
dependently associated with an increased risk of both stage-III and stage-IV 
CKD, but not all cause mortality in a large cohort of LTx patients, independent 
of potential confounders.  
These findings are reason for concern. Waiting times for LTx have continued to 
increase due to expanding recipient criteria. Likewise donation criteria have 
also expanded. Patients as well as organs transplanted are generally in worse 
condition now than several years ago and LTx recipients are therefore at 
increased risk of complications after LTx, amongst which CKD (37). If the 




association of former smoking and CKD after LTx is confirmed in other 
studies, it would be relevant to gain further insight in the biology of this 
association. For the moment, it would seem prudent to consider former smokers 
at increased renal risk and avoid additional renal risks as much as possible.  
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Renal transplant recipients (RTR) are often advised to refrain from alcohol 
because of possible interaction with their immunosuppressive medication. 
While moderate alcohol consumption is associated with reduced risk of 
diabetes and mortality in the general population, this is unknown for RTR. 
Therefore, we investigated the association of alcohol consumption with new 
onset of diabetes after transplantation (NODAT), mortality and graft failure in 
RTR. RTR were investigated between 2001-2003. Alcohol consumption was 
assessed by self-report. Mortality and graft failure was recorded until May 
2009. 600 RTR were studied (age 51±12 years, 55% men). Of these RTR, 48% 
were abstainers, 38% had light alcohol intake, 13% had moderate intake and 
1% were heavy consumers. Moderate alcohol consumption was associated with 
a lower risk of developing NODAT over the follow-up period than was 
abstention (OR=0.36 [0.2-0.6], P=<0.001). During follow-up for 7.0 [6.2–7.5] 
years, 133 recipients died. In Cox-regression analyses moderate alcohol 
consumption was associated with lower mortality period than was abstention 
(HR=0.40[0.2-0.8], P=0.009). Adjustment for confounders, including age and 
smoking did not materially change this association. No association was found 
between alcohol consumption and graft failure. Moderate alcohol consumption 
is associated with low prevalence of NODAT and reduced risk for mortality in 
RTR, in line with findings in the general population. These findings refute the 
common advice to refrain from alcohol in RTR. 






Renal transplantation is the treatment of choice for patients with end-stage renal 
disease and allows freedom from lifestyle restrictions such as a strict diet (1). 
Short-term outcome after renal transplantation has improved substantially in the 
past decades, but long-term graft and patient survival have not improved in a 
similar manner (2). One main reason for persisting poor long-term outcome is 
premature death due to cardiovascular diseases (CVD), with incidence of CVD 
estimated to be 4-6 times higher in renal transplant recipients (RTR) than in the 
general population (3). 
Interventions targeting modifiable risk factors such as hypertension, 
dyslipidemia, and physical activity, can improve outcome in RTR (4-6). 
Moderate alcohol consumption could be a behavioral lifestyle factor for 
lowering of risk of premature death, because numerous studies in the general 
population have demonstrated that moderate alcohol intake (1-3 units per day) 
is associated with reduced risk of diabetes, mortality and CVD compared to 
abstainers and sporadic users, while there is again an increased risk with intake 
above 3 units per day (7). 
The KIDIGO Practice Guideline for the Care of Kidney Transplant Recipients 
does not mention specific alcohol restrictions for RTR (8). Accordingly, 
transplantation centers usually do not specifically advise RTR to refrain from 
post-transplantation alcohol use. Advice on the internet is, however, different. 
RTR are advised not to use alcohol for one year after transplantation, to avoid 
alcohol unless the doctor gives permission, or not to use any alcohol at all 
(9,10) . 
One study showed that alcohol abuse is rare after kidney transplantation and 
that intake among RTR is generally low (11). No data are available on the 
relation between post-transplant alcohol use and long-term outcome. 
Therefore, we aimed to investigate the prevalence and correlates of alcohol 
consumption in RTR in a large single-center cohort. Furthermore, we aimed to 
investigate whether alcohol consumption is associated with new onset of 




diabetes after transplantation (NODAT), all-cause mortality and graft survival 
in these patients.  
 
Patients and Methods 
 
Research Design and Subjects 
The Institutional Review Board approved the study protocol (METc 2001/039), 
which was incorporated in the outpatient follow-up of the Groningen Renal 
Transplant Program. The outpatient follow-up constitutes a continuous 
surveillance system in which patients visit the outpatient clinic with declining 
frequency, in accordance with American Transplantation Society guidelines, i.e. 
ranging from twice a week immediately after hospital discharge to twice a year 
long-term after transplantation (55). All adult allograft recipients between 
August 2001 and July 2003 who survived with a functioning allograft beyond 
the first year after transplantation (1 year post transplant was considered 
baseline) were eligible to participate at their next visit to the outpatient clinic 
(index date). The group that did not sign informed consent was comparable 
with the group that did sign informed consent with respect to age, sex, body 
mass index, serum creatinine, creatinine clearance, and proteinuria. In patients 
with fever or other signs of infection (e.g. complaints of upper respiratory tract 
infection or urinary tract infection), baseline visits were postponed until 
symptoms had resolved. Patients with overt congestive heart failure and 
patients diagnosed with cancer other than cured skin cancer were not 
considered eligible for the study. A total of 606 out of 847 eligible renal 
transplant recipients signed written informed consent. Information on alcohol 
consumption was available in 600 patients. Alcoholism is considered a 
contraindication for transplantation in our center. 
 
Endpoints of the study 
The primary endpoints of this study were recipient mortality and graft failure. 
Graft failure was defined as a return to dialysis or re-transplantation. The 





continuous surveillance system of the outpatient program ensures up-to-date 
information on patient status and cause of death. We contacted general 
practitioners or referring nephrologists if the status of a patient was unknown. 
Mortality and graft loss were recorded until May 2009. Cause of death was 
obtained by linking the number of the death certificate to the primary cause of 
death as coded by a physician from the Central Bureau of Statistics. Causes of 
death were coded according to the International Classification of Diseases, 9
th
 
revision (ICD-9) (56). Cardiovascular death was defined as death in which the 
principal cause of death was cardiovascular in nature, using ICD-9 codes 410-
447. There was no loss due to follow-up. NODAT was defined by fasting 
plasma glucose concentration was ≥7.0 mmol/l and/or use of anti-diabetic 
medication (57). 
 
Renal Transplant Characteristics 
Groningen Renal Transplant Database contains information on all renal 
transplantations performed at our center since 1968. Relevant transplant 
characteristics such as age, gender and date of transplantation were extracted 
from this database. Current medication was taken from the medical record. 
Smoking status and cardiovascular history were obtained using a self-report 
questionnaire. Cardiovascular disease history was considered positive if 
participants had a myocardial infarction (MI), transient ischemic attack (TIA) 
or cerebrovascular accident (CVA). 
 
Measurements and definitions 
Quantitative information on alcohol consumption was obtained by self-report 
questionnaire. Accordingly RTR were categorized into 4 groups of alcohol 
consumption (58): abstainers, light consumption (up to 10 gram per day), 
moderate consumption (10-30 gram per day) and high alcohol consumption 
(more than 30 gram per day). BMI, waist circumference and blood pressure 
were determined as described previously (56). MS was defined by the 




definition of the National Cholesterol Education Program Expert Panel (NCEP-
ATPІІІ) as described earlier (56).  
 
Blood was drawn after an overnight fasting period. We measured serum 
creatinine, serum triglycerides, total cholesterol, high-density lipoproteins-
(HDL-)cholesterol, plasma glucose and HbA1c as described previously. Low-
density lipoproteins (LDL) cholesterol was calculated using the Friedewald 
formula (59). Serum high sensitive C-reactive protein (hsCRP) was assessed 
with a high sensitivity CRP ELISA assay as described before (60). We 
performed uniform measurement of Gammaglutamyltransferase (GGT), 
asparaat-amino-transferase (ASAT), alanine-amino-transferase (ALAT), 
Alkaline phosphatase (AP) and lactaatdehydrogenase (LDH) activity in serum 
as described before.  
 
Creatinine clearance was calculated from 24-hour urinary creatinine excretion 
and serum creatinine. Total urinary protein concentration was analyzed using 
the Biuret reaction (MEGA AU 510, Merck Diagnostica, Darmstadt, Germany) 
and proteinuria was defined as urinary protein excretion >0.5 g per 24 hours. 
 
Statistical analysis 
Data were analyzed with SPSS version 16.0 (SPSS Inc., Chicago, IL) and 
GraphPad Prism version 4.03 (GraphPad Software Inc., San Diego, CA). 
Normally distributed variables are expressed as mean ± standard deviation, 
whereas skewed distributed variables are given as median (25th-75
th
 
percentile), percentages were used to summarize categorical variables. Log-
transformation was used for variables with a skewed distribution. Hazard ratio’s 
(HR) are reported with 95% confidence interval [95% CI].  
 
We analyzed recipient-related characteristics separately for the four categories 
of alcohol consumption. Student’s t-test or Kruskal Wallis test was used to 
compare means for continuous variables and with Chi-square for categorical 





variables. Logistic regression analyses were used to analyze the association 
between alcohol consumption and risk for NODAT, for this analyses 17 RTR 
with pre-transplantation diabetes at baseline were excluded. To analyze whether 
alcohol consumption is associated with mortality and graft failure, we first 
performed Kaplan-Meier analyses with a Log-rank test. Univariate and 
multivariate Cox-regression analyses were performed to investigate whether 
alcohol consumption is independently associated with mortality and graft 
failure. Each baseline group of alcohol consumption was compared with the 




A total of 600 RTR were studied (mean age 51±12 years, 55% men). Baseline 
characteristics according to alcohol consumption are shown in table 1. Of the 
600 patients providing information on alcohol use, 288 (48%) were abstainers, 
226 (38%) had light intake (< 10 gram per day), 78 (13%) had moderate intake 
(10-30 g per day) and 8 (1%) – all men – had high intake (>30 g per day).  
 
 





<10 g per day 
N=226 
10-30 g per 
day 
N=78 










Age, yr 53 ± 13 50 ± 12 52 ± 9 50 ± 11 0.1 
Male, n (%) 105 (36) 226 (67)* 65(83) * 8 (100) * <0.001 
Being unfit to 
work, n (%) 
78 (27) 62 (27) 21(27) 2 (25) 0.9 









29 [14-50] 28 [13-52] 21 [9-33] * 26 [20-38] 0.01 
Time between ntx 
and inclusion , yr 
6.0[3-12] 6.1 [3-11] 5.8 [3-11] 2.6 [1-9] 0.5 
Living donor, n (%) 29 (10)  37 (16) 
16 (21) 





121 (42) 106 (47) 
40(51) 







Infarction, n (%) 
27(9) 14 (6) 
6(8) 
1 (13) 0.5 
TIA/CVA, n (%) 16(6) 15 (7) 
2(3) 
0 (0) 0.5 
Substance use 
    
 
Current smoking, n 
(%) 
54 (14) 55 (24) 20(26) 4 (50) 0.08 
Past smoking, n 
(%) 
105 (37)  102 (45)* 43(55)* 3 (38)  0.02 
History and current 
smoking, n (%) 
159 (55) 157(69)* 63(81)* 7(88) * <0.001 
Body composition      
BMI, kg/m
2
 26±5 26±4 25±4 26±2 0.3 
Waist 
circumference, men (cm) 
100 ± 13 100 ± 13 99 ± 12 100 ± 10 0.9 
       Waist 
circumference, women 
(cm) 
95 ± 15 94±15 86±10 - 0.1 
Blood pressure      
Systolic BP, mmHg 153 ± 24 153 ± 21 152± 22 166 ± 17 0.5 





Diastolic BP, mmHg 89 ± 10  90 ± 9 90± 9 104 ± 5* 0.001 
Use of antihypertensive 
drugs, n (%)  
246 (85) 201 (89) 69(88) 8 (100) 0.4 
Lipids      
Total cholesterol, mmol/l            5.5 ± 1.0            5.6 ± 1.2                 5.7 ± 1.0 5.8 ± 0.7 0.5 
HDL cholesterol, mmol/l
  
             1.1 ±0.2 1.1 ±0.3 
 
1.1 ±0.3 
1.3 ±0.6 0.2 
LDL cholesterol, mmol/l               3.5 ±0.9 3.6 ± 1.1 3.7 ± 1.0 3.3 ± 0.7 0.07 
Triglycerides, mmol/l          2.0 [1.4-2.8] 1.9 [1.3-2.5] 
 
1.8 [1.4-2.3] 
2.4 [1.8-3.6] 0.1 
Statins, n (%)            145 (50)       102 (45) 
 
41(53) 
   8 (100)* 0.02 
Glucose homeostasis      
Glucose, mmol/l 4.9±1.4 4.8 ±1.5 4.8 ±1.1 4.7 ±0.5  0.9 
Insulin, (µmol/L) 12.0 [9-17] 10.6 [8-15]* 9.1 [7-13]* 9.0 [6-15] 0.001 
Hba1c, % 6.6±1.1 6.5 ± 1.0 6.5 ± 1.1 6.3 ± 0.8   0.5 
NODAT, n (%) 73 (25) 42(19) 9(12)* 1(13) 0.03 
Pre transplant diabetes, 
n (%) 
13(5) 12(5) 3(4) 0(0) 0.8 
Metabolic Syndrome n, 
(%) 
           196 (68)        145 (64) 
 
40(51)* 
         4 (50)   0.04 
Inflammation      
CRP, mg/l 2.2 [1-5] 1.9 [1-5] 1.8 [1-4] 1.0 [0-3] 0.2 
Immunosuppressive 
medications 
     
Daily prednisolone dose, 
mg/day 
10.0 [8-10] 10.0 [8-10] 10.0 [8-10] 10.0 [8-10] 0.3 
Calcineurin inhibitors, n 
(%) 
224 (78) 183 (81) 56(72) 7 (88) 0.3 






205 (71) 170 (75) 62(79) 7 (88) 0.3 
Renal allograft function      
Serum creatinine, Men 
(µmol/l) 
137 [119-171] 146 [125-177] 144 [124-182] 166 [145-214]* 0.03 
Serum creatinine, 
Women (µmol/l) 
119 [99-149] 127 [97-156] 127 [106-155] - 0.7 
Creatinine clearance, 
ml/min 
60 [45-75] 60 [47-76] 66 [51-81] 58 [45-76] 0.2 
Proteinuria, g/24h 0.2 [0.0-0.5] 0.3 [0.1-0.6] 0.3 [0.1-0.5] 0.4 [0.2-0.8] 0.2 
Liver function      
GGT, U/L Men 25 [17-38] 24 [19-38] 26 [18-42] 33 [22-49] 0.4 
       GGT, U/L Women 24 [17-40] 23 [16-35] 22 [20-34] - 0.6 
ASAT, U/L 23 [19-28] 22 [19-26] 23 [18-27] 21 [18-29] 0.8 
ALAT, U/L 17 [13-23] 29 [14-25] 19 [14-26] 22 [14-26] 0.8 
AP, U/L 74 [60-96] 71[55-94] 72[57-84] 65[50-102] 0.4 






Data are represented as mean ± SD, or median [95% CI]. Differences were tested by t-test or 
Kruskal Wallis test for continuous variables and with Chi-square for categorical variables. 
*Group significantly different from reference group (abstainers), P <0.05. Time between ntx 
and inclusion, yr, time between transplantation and inclusion, years; a Acute rejection treatment 
with high dose corticosteroids. TIA, transient ischemic attack; CVA, cerebrovascular accident; 
BMI, body mass index; BP, blood pressure; HDL, high density lipoprotein; LDL, low density 
lipoprotein; NODAT, new onset of diabetes after transplantation; CRP, C-reactive protein; 
GGT; gammaglutamyltransferase; ASAT, asparaat-amino-transferase; ALAT, alanine-amino-
transferase; AP; alkaline phosphatase LDH, lactaatdehydrogenase  
 





Moderate alcohol consumers were more likely to have a shorter dialysis time, a 
living donor and higher LDL-cholesterol. Alcohol consumption was positively 
associated with male gender, smoking and past smoking, diastolic blood 
pressure and use of statins and serum creatinine concentrations in men. There 
was an inverse association between alcohol consumption and prevalence of 
Metabolic syndrome (MS), fasting insulin concentrations and prevalence of 
NODAT. Total prevalence NODAT was 125 (21%). Results of univariate and 
multivariate logistic regression analyses for alcohol consumption and risk for 
NODAT are shown in table 2. Moderate alcohol consumption was strongly 
associated with low prevalence of NODAT (Odds ratio= 0.37 [0.17-0.78], 
P=0.008). A total of 385 RTR (64%) fulfilled the criteria of MS. Prevalence of 
MS decreased according to increasing alcohol consumption (P= 0.04). 
 




Model 1: Crude model  Model 2: model 1 + adjustments for age and sex 
Model 3: model 2 + current smoking and past smoking  Model 4: model 3 + BMI 




During follow-up for 7.0 [6.2 – 7.5] years, 133 RTR died and 52 RTR suffered 
graft failure necessitating their return to dialysis. In the group with moderate 
alcohol consumption 9 (12%) RTR died during follow-up, whereas this number 
was 75 (26%) for the group with no consumption, 47 (21%) in the group with 
light consumption (Log-rank test P=0.02, fig. 1a), and 2 (25%) in the group 
with high alcohol consumption.  

















Figure 1a. Kaplan Meier curves of mortality to alcohol consumption, tested with Log-rank test 
(P= 0.02). 
 
Results of univariate and multivariate Cox-regression analyses for associations 
of alcohol consumption with mortality are presented in table 3. Moderate 
alcohol consumption was strongly associated with reduced risk for mortality 
(model 1) in univariate analyses (HR=0.40[0.2-0.8], P=0.009). Upon 
multivariate analyses, these associations weakened after adjustment for age and 
sex (model 2). Adjustment for current smoking and past smoking strengthened 
the association (model 3). Further adjustments for BMI, use of statins and LDL-





cholesterol (model 4) living donor and dialysis time (model 5) and serum 
creatinine (model 6) did not materially changed the association. 
 




Model 1: Crude model  
Model 2: model 1 + adjustments for age and sex 
Model 3: model 2 + current smoking and past smoking  
Model 4: model 3 + BMI, statin use, and LDL-cholesterol 
Model 5: model 4 + living donor and dialysis time 
Model 6: model 5 + serum creatinine 
 
 
In the group with moderate alcohol consumption 9 (12%) RTR developed graft 
failure during follow-up, whereas this number was 23 (8%) for the group of no 
alcohol consumption and 19 (8%) for the group with light alcohol consumption 
(Log-rank test P=0.6, fig.1b). In the group with high alcohol consumption 1 
(12.5%) RTR developed graft failure. In a univariate Cox-regression analysis 
moderate alcohol intake was not associated with graft failure (HR =1.44 [0.7-
3.1], P=0.4). 






















Figure 1b. Kaplan Meier curves of graft loss according to alcohol consumption, tested with 
Log-rank test (P= 0.6). 
Discussion  
This is the first study to report on habitual alcohol consumption, NODAT and 
all cause mortality in RTR. It suggests that moderate alcohol consumption has 
protective effects in RTR that correspond to those in the general population, 
despite differences in disease burden and medication use. In particular, 
moderate alcohol consumption is associated with lower risk for NODAT and 
all-cause mortality. No association was found between alcohol consumption 
and graft loss.  
The prevalence of alcohol consumption in our study population (52%) is similar 
to the prevalence and severity of alcohol consumption in RTR reported by 
Fiertz (11), and lower than in the general population, where alcohol 
consumption is approximately 89% in men and 74% in women (12). This 
suggests that RTR limit alcohol consumption, either spontaneously or as a 
consequence of advice. In agreement with guidelines, we do not actively advise 





RTR to refrain from post-transplantation alcohol use in our center. On the other 
hand, advice on the internet does (9,10) and there may be a general tendency for 
patients and physicians to adhere to this. Reasons for advising against alcohol 
consumption could be several. Due to the immunosuppressive regime, 
transplant doctors are often cautious with advice on alcohol consumption. It 
may for instance be thought that great amounts of alcohol interfere with liver 
metabolism, in addition to calcineurin inhibitors, such as cyclosporine, stressing 
the liver. Another reason may be the data provided by the only other 
prospective study of the effects of alcohol consumption in RTR. In this study, 
Gueye et al. analyzed renal graft and patient survival in 425 RTR with alcohol 
dependence before transplantation compared to 60 523 RTR without alcohol 
dependence (13), rather than average daily intake after transplantation, as we 
did. They concluded that alcohol dependence before transplantation is a risk 
factor for renal graft failure and death and advised against use of alcohol in 
RTR. Our study suggests that average daily intake of alcohol after 
transplantation cannot be compared to alcohol dependence before 
transplantation. 
New onset diabetes is a common complication of transplantation and a major 
risk factor for graft failure and mortality in RTR (14,15). Traditional risk 
factors like obesity, diabetes mellitus, dyslipidemia and hypertension are often 
seen in transplantation patients and cluster in the MS (16). Our data confirm 
this with a prevalence MS of 64%.  
While there is no other literature addressing alcohol consumption and long-term 
outcome in RTR, the inverse association between alcohol consumption and 
cardiovascular diseases in the general population is well documented. Moderate 
alcohol consumption is associated with a decreased risk for myocardial 
infarction (17,18), heart failure (19,20) and ischemic stroke (21-23). It also 
reduces the risk of myocardial and all-cause mortality (24-28). Moderate 
alcohol consumption is also associated with a decreased risk of developing type 
2 diabetes (29,30). Our study shows that moderate alcohol consumption is 
associated with 60% decreased risk for all cause mortality, compared to the 




group of abstainers. The risk reduction of moderate alcohol consumption in the 
general population is estimated to be between 20-30%. The magnitude of risk 
reduction seems to be higher in RTR. This is in line with a previous study 
which showed larger risk reductions for those with an increased cardiovascular 
risk (31).  
There is little known about the influence of alcohol consumption on renal 
function and graft survival and results are inconsistent. Studies in general 
population cohorts suggest no adverse effects of alcohol consumption and even 
a protective effect of alcohol consumption on renal function (32,33) has been 
described. Other studies suggest a negative link between alcohol intake and 
kidney function. In an Australian population-based study all alcohol intake of 
≥30 g/day was independently associated with an increased risk of albuminuria 
(34). Another population based study (35) showed a 4-fold increased risk of 
end-stage renal disease in subjects who consumed ≥2 units alcohol per day. It 
has been argued that the pressor effect of alcohol might increase the risk for 
renal disease (36). Indeed, we found evidence for a decreased renal function in 
the group with high alcohol consumption in our study. Serum creatinine was 
significantly higher in the group with high alcohol consumption and there was a 
trend for a lower creatinine clearance and higher proteinuria with high alcohol 
consumption. Systolic blood pressure was also significantly higher in the RTR 
with high alcohol consumption. Although we found no significant association 
between alcohol consumption and graft failure, this is possibly the consequence 
of the group being very small, increased systolic blood pressure and increased 
urinary protein excretion are consistent with an adverse effect of heavy alcohol 
consumption on graft function.  
We anticipated that a potential association of moderate alcohol consumption 
with mortality could be confounded by other risk factors for mortality or a 
healthier lifestyle. We found, however that the association between alcohol 
consumption and all-cause mortality was not materially affected by adjustments 
for current smoking and past smoking, BMI and LDL-cholesterol. Tobacco use 
is an important confounder in the relationship between alcohol and mortality. 





Tobacco use is often greater in people who drink alcohol (37). History of 
smoking and current smoking in our population increased from 159 (55%) to 
157 (69%), 63 (81%) and 7 (88%) according to increasing alcohol consumption 
(P< 0.001). Studies showed that smoking has a major negative impact on 
mortality and graft survival in RTR (38,39). The strengthening of the 
association after adjustment for smoking (table 2, model 3) suggests that 
alcohol consumption has a stronger protective effect if it is not combined with 
smoking. It has been argued that moderate drinkers may represent a relatively 
healthy subpopulation, with a general healthier lifestyle, related to the fact that 
people in a poor overall condition are less likely to consume alcohol, which 
may explain a small proportion of the effect of alcohol consumption on 
mortality (40). Various studies have removed the effect of so called ‘sick 
quitters’ by taking lifelong abstainers as reference group and looked at the 
effects independent of other healthy lifestyle factors, showing that moderate 
alcohol consumption is causally related to a lower risk for cardiovascular 
diseases (41).  
There is substantial evidence to support a causal relationship between alcohol 
consumption and CVD in the general population (42). The protective effect of 
moderate alcohol consumption can be explained by several mechanisms. An 
important way by which alcohol consumption can modulate the CVD risk is by 
changes in lipid profile. Moderate alcohol consumption is associated with 
higher HDL- cholesterol and apolipoprotein A1 levels (43,44). Alcohol also has 
been shown to decrease platelet aggregation and lower concentrations of plasma 
fibrinogen (45,46). Another important mechanism that could modulate CVD 
risk is by lowering insulin resistance. Moderate alcohol consumption increases 
the insulin sensitivity and thereby lowers the risk for developing diabetes 
(29,47,48). The same mechanisms could be relevant to reduce mortality risk in 
RTR. Our results indicate that RTR with moderate alcohol consumption had 
lower insulin levels and lower prevalence of diabetes, implicating a possible 
effect of alcohol on insulin sensitivity. Moderate consumers also had higher 
levels of LDL- cholesterol and lower triglycerides (borderline significant). The 




small differences in lipid levels could partly be explained by the frequent use of 
statins among our RTR.  
The strength of our study is its prospective design. RTR in this study were 
closely monitored by regular check-ups in our clinic, which give complete 
information on patient status. Some limitations of our study warrant 
consideration. First, this study relied on self-reported data. Recall bias and 
social desirability bias are unfortunately unavoidable and could influence 
internal validation. Self-reported alcohol intake is generally under reported 
(49). However, studies have found that questionnaires provide enough validity 
for ranking participants on alcohol consumption (50). Second, we acquired 
information on average daily intake with no details on drinking patterns. The 
cardio protective effect occurs in regular drinkers and not in binge and irregular 
heavy drinkers (51). Moreover, our study used a single measurement of alcohol 
consumption and did not take into account any changes in alcohol consumption 
over time. Finally, it was a single center study in a predominantly Caucasian 
population. In our study prevalence of diabetes and body mass index were 
relatively low. The contribution of diabetes mellitus to end-stage renal disease 
in the Netherlands as compared its surrounding countries is relatively low (52-
54). This may at least in part explain the low prevalence of diabetes in our 
study. Similarly, the relatively low BMI may be a reflection of the relatively 
low contribution of type 2 diabetes to end-stage renal disease in our population.  
 
This study shows that moderate alcohol consumption is inversely associated 
with NODAT and all cause mortality in RTR. So, in contrast to common belief, 
drinking moderate amounts of alcohol does not appear to be detrimental and 
may be protective against diabetes and mortality in RTR, similar to the general 
population, despite differences in disease burden and medication use. Further 
research is needed to confirm these findings and to investigate the relationship 
between alcohol consumption and graft survival.  
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Many proteinuric renal conditions are accompanied by renal inflammation. 
Nicotine is known to have anti-inflammatory properties, and is used in oral 
form to quit smoking. A potential anti-inflammatory role of nicotine in 
proteinuric renal diseases has not been investigated to date. We therefore 
evaluated the effects of oral nicotine in a rat model of proteinuria-induced renal 
inflammation. We used a well-established model of adult (24 wk of age) male 
Munich-Wistar-Frömter rats. Animals were given 3 different physiological 
doses of Nicotine in drinking water for 28 weeks, till 52 wk of age (long term). 
A group without nicotine served as parallel control. At 52 weeks of age, the 
control group had 2.1 times reduction in creatinine clearance, 3.2 times increase 
in urinary protein excretion, increased focal glomerulosclerosis (FGS) score, 
glomerular desmin deposition and podocytopathy (podocin loss) and higher 
accumulation of macrophages and myofibroblasts compared to 24 wk animals. 
Oral treatment with nicotine dose-dependently preserved renal function and 
halted proteinuria progression, which were independent of blood pressure 
reduction. Oral nicotine also reduced FGS, desmin deposition and podocin loss 
and density of renal macrophages and myofibroblasts. Nicotine also reduced the 
level of gene expression of the renal inflammatory markers MCP-1 and 
VCAM-1. In conclusion, long term oral nicotine preserved kidney function, 
reduced proteinuria, reduced renal inflammation and protected progression of 
renal structural damage in a rat model of proteinuria. We further suggest 
evaluating nicotine as a potential additional therapeutic option for treating 
proteinuric kidney diseases. 
 







Reduction of blood pressure and proteinuria currently are the cornerstone of 
renoprotective intervention. However, despite correction of hypertension and 
reduction of proteinuria, renoprotection is often incomplete and many patients 
progress towards renal failure. Even forced down titration of proteinuria by 
dual Renin Aldosterone Angiotensin System (RAAS) intervention 
(ONTARGET trial) or Angiotensin Converting Enzyme (ACE)-inhibition so far 
was not successful to improve renal outcome (1). Rather, under very low salt 
conditions such stringent measures may worsen outcome (2). This indicates the 
need for additional treatment modalities for renoprotection: not only in trying to 
reduce proteinuria even further, but also in reducing the harmful effects 
downstream of proteinuria. Evidence for this approach came amongst others 
from a bicarbonate study in hypertensive nephropathy patients, showing that 
oral bicarbonate is an effective kidney-protective measure in adjunction to 
blood pressure control and ACE-inhibition, most likely through reduction of 
tubulo-interstitial injury (3,3). Similarly combination of vitamin D with AT1 
receptor blocker reduces harmful effects of diabetic nephropathy (4). It is well 
recognized that proteinuria leads to renal inflammation and fibrosis, most likely 
via tubular activation by filtered proteins, leading to the production of a cascade 
of mediators by tubular cells, including chemo- attractants for leukocytes such 
as MCP-1 (5). Consequence is an influx of monocytes and macrophages, which 
mediate renal inflammation and fibrosis (6) . 
Renal inflammation is seen in many proteinuric renal diseases. Chronic renal 
inflammation is related to progressive decline in kidney function, 
glomerulosclerosis, interstitial damage (7) and resistance to renoprotective 
therapy (8). Recruited monocytes and macrophages orchestrate inflammation 
related damage. Reduction of inflammation by immunosuppressive drugs has 
been shown to slow down renal dysfunction with reduction in 
glomerulosclerosis and interstitial inflammation (9-12). 




Smoking is a risk factor of development and progression of diabetic 
nephropathy, a risk factor for progression of chronic kidney disease to end stage 
kidney disease (13,14) and also a risk factor for graft failure in renal transplant 
patients (13). Cigarette smoke contains many compounds of hydrophilic, 
lipophilic and ambiphilic nature, which together are supposed to mediate 
cigarette smoking related renal damage. Whether nicotine contributes to 
harmful effects of cigarette smoke on renal function is not clear. Nicotine is a 
major constituent of cigarette smoke and used widely in oral form to quit 
smoking (15-20). Previous studies have shown nicotine to be clinically 
beneficial in many diseases in which an inflammatory component plays a role 
(21). Notably, nicotine has been shown beneficial in ulcerative colitis (22), 
sepsis (23), hypersensitivity penumonitis (24), renal ischemic reperfusion injury 
(25) and experimental type 1 diabetes (26).  
Nicotine exerts its anti-inflammatory effects via α-7 nicotinic Acetylcholine 
Receptor (α-7nAchR) (27-29) which are present on macrophages and 
peritubular capillaries in kidneys (25,30). Thus, nicotine might have 
renoprotective potential by its anti-inflammatory properties, but this hypothesis 
has not been tested so far in chronic proteinuric settings. In this study, we 
therefore evaluated the effects of long term oral nicotine on renal function and 
inflammation in Munich-Wistar-Fromter (MWF) rats, which develop 
spontaneous, proteinuria-induced renal inflammation (31-34).  
 
We found that long term oral nicotine slowed down the rise in proteinuria, 
slowed down loss of kidney function and reduced glomerular injury and 






Animals and housing 





Inbred 20 weeks male Munich-Wistar-Fromter rats (n=46) were obtained from 
Harlan, USA. All animals were housed in temperature controlled 12h light/12h 
dark rooms and had free access to food and drinking water. All animals 
received human care in compliance with the Principles of Laboratory Animal 
Care (NIH Publication no. 85-23, revised 1996) and the protocol was approved 
by University Medical Center Groningen Animal Ethical Committee. 
 
Experimental setup 
After acclimatization for 2 weeks, animals were trained for tail cuff blood 
pressure measurement (CODA 6, Kent Scientific Corporation, USA) daily for 
another 2 weeks. At 24 week of age baseline blood pressure was measured, 
venous blood was withdrawn and 24h urine was collected in metabolic cages. 
For baseline histology six rats were sacrificed at the age of 24 weeks. The other 
animals were randomly assigned to four different groups. Rats were given 
either of 3 different concentrations 20 mg/l (n=10; N20), 60 mg/l (n=10; N60) 
and 100 mg/l (n=10; N100) of nicotine mixed with 0.5% sodium saccharin as 
sweetening agent ad-libitum in drinking water. Control group (n=10; CON) 
only received water sweetened with 0.5% sodium saccharin. Treatment 
continued for 28 weeks (until 52 weeks of age). One animal in N60 was 
sacrificed prematurely because of tooth malformation due to which the animal 
was unable to eat and lost weight. One animal in N20 was sacrificed because of 
a bone tumor. The tumor formation is unlikely to be related to nicotine since it 
was a sporadic case which might be related to aging. Both the animals were 
excluded from all analyses.  
 
Nicotine intake and Cotinine measurement 
Amount of nicotine intake per day is equal to 24h water intake of individual rat 
in metabolic cages X concentration of nicotine in water. Cumulative dose of 
nicotine intake was calculated by calculating the area under curve of nicotine 
intake over 28 treatment weeks. Cotinine is a major and stable metabolite of 
nicotine and used to quantify smoking (35). Cotinine was measured in plasma 




to quantify the amount of nicotine by Immunometeric Assay IMMULITE 
Tm 
 
2000 from Siemens. The range of measurement was >10 ng/ml and <500 ng/ml. 
 
Clinico-pathological parameters  
Blood pressure was measured in trained awake animals with tail-cuff method. 
24h urine and venous blood were collected at every 4 weeks until the end of the 
study. 24h urine were collected and stored at -20 °C until analyses were 
performed. Venous blood was collected with heparin and stored in -80 °C. 
Urinary and plasma creatinine and urinary protein were measured by multi-test 
analyzer system (Roche Modular; F.Hoffmann-La Roche Ltd, Basel, 
Switzerland). Creatinine clearance was calculated from 24h urinary volume, 
plasma and urinary creatinine (36). 
 
Sacrifice and organs 
Animals were sacrificed under isofluran-induced general anesthesia by cutting 
the diaphragm. Animals were flushed with 0.9% NaCl, kidneys were harvested, 
and weights were measured and were partly stored in -80 °C and partly fixed in 
4% formalin followed by embedment in paraffin. 
 
Morphological analysis  
4 μm thick formalin fixed paraffin sections were deparaffinized and stained for 
periodic acid Schiff (PAS) for quantification of focal segmental 
glomerulosclerosis (GS). GS was semi quantitatively scored in a blinded 
fashion by determining the level of mesangial expansion and focal adhesion in 
each quadrant in a glomerulus and expressed on a scale from 0 to 4. If 25% of 
the glomerulus was affected, it was scored as 1, 50% as 2, 75% as 3 and 100% 
as 4. In total, 50 glomeruli per kidney were analyzed, and the total GS score 
was calculated by multiplying the score by the percentage of glomeruli with the 
same GS score. The sum of these scores gives the total GS score from 0 to 200 
(36).  






Deparaffinized and rehydrated sections (4 µm) were subjected
 
to heat-induced 
antigen retrieval by overnight incubation in a 0.1 M Tris/HCl buffer (pH 9.0) at 
80°C. Endogenous peroxidase
 
was blocked with 0.3% H2O2 in phosphate-
buffered saline (PBS)
 
for 30 min and sections were incubated with ED1 
antibody
 
to visualize monocytes/macrophages (Serotec, Oxford, UK) or anti 
smooth muscle actin (A5228, Sigma-Aldrich, Zwijndrecht, The Netherlands) to 
show myofibroblasts, anti-desmin antibody to show podocyte injury (Novus 
Biologicals, USA) and anti-podocin antibody to show podocytopathy (Sigma, 
USA) for 60 min at room temperature. Binding of
 
the antibody was detected 
using sequential incubations with horseradish 
 
peroxidase (HRP)-labelled rabbit 
anti-mouse and HRP-labelled Swine
 
anti-rabbit antibodies (DAKO); both for 30 
min. Peroxidase activity
 
was developed using 3-Amino-9-Ethylcarbazole 
(AEC) for 15 min. Sections were counterstained with haematoxylin.
 
Monocyte/macrophages influx and myofibroblasts were quantified in 50 
cortical and outer medullary areas using image processing and analysis 
programme (ImageJ) magnified 200 times in a standardized and blinded 
fashion. Desmin and podocin positivity was quantified in a similar fashion. The 
results are presented as percentage of positively stained area relative to total 
area measured. Arteries were excluded from analysis. 
 
Quantitative real time RT-PCR (qPCR)  
Total RNA was extracted from 25-30 mg of frozen rat kidney tissue using 
RNeasy mini kit from QIAGEN. cDNA was synthesized using 1 μg of RNA by 
QuantiTect Reverse Trasncriptase kit (QIAGEN, catalogue number 205313). 
PCRs were performed in a 10 μl reaction containing 6.6 ng of RNA and using 
2X Sensimix CYBR Green mastermix kit (QIAGEN catalogue number QT 
650). qPCR was performed in C1000 Thermal cycle from Biorad. On demand 
primers for GAPDH, MCP-1, VCAM-1 were obtained from QIAGEN. Results 
are expressed relative to CON after sacrifice at 52 wk of age after normalizing 
for GAPDH a house keeping gene.  





Statistical analysis was performed using Spss 14. Area under curve and figures 
were made by GraphPad Prism (version 4.00; GraphPad Software, Inc., San 
Diego, CA). Parametric values are expressed as mean (standard error of the 
mean). Non parametric values are expressed as median (Inter Quartile Range) 
and were log transformed for further analysis. ANOVA with post-hoc tests 
according Tukey for comparison of treatment groups and controls at 52 weeks 
and general linear model for repeated measurements for comparison of the time 
course of proteinuria between treatment groups were used. P < 0.05 was 




Nicotine intake and clinico-pathological parameters  
Parameters concerning nicotine intake and clinico-pathological markers are 
shown in table 1. Cumulative nicotine intake was calculated from 
concentrations added to drinking water and volume of water intake. Nicotine 
intake was significantly different among the three treatment groups and there 
was no nicotine intake in the control (CON) group. Analogous, there was a 
dose-dependent difference in plasma cotinine concentrations between the 
treatment groups and no detectable plasma cotinine in the CON group. CON 
group had significantly higher plasma triglyceride compared to N60 and N100. 
There were no differences in body weight, water intake and systolic blood 
pressure among the groups during the experiment.  
 
Clinicopathological characteristics at baseline and after 28 weeks of oral 













Abbreviations: CON: MWF without nicotine; N20: MWF rats treated with 20mg/l nicotine; 
N60: MWF rats treated with 60mg/l nicotine; N100: MWF rats treated with 100mg/l nicotine. 
*p <0.05 vs control **p<0.01 vs control *** p<0.001 vs control ; & p<0.001 vs N20; $ p<0.001 
vs N60. Parametrical values are given as mean (SEM) whereas non parametrical values are 
given as median [inter quartile range]. 
 
Renal parameters  
Plasma creatinine increased from 26±2 μmol/l at 24 weeks of age in the 
baseline group to 50±7 μmol/l at 52 weeks of age after 28 weeks of placebo 
with sodium saccharin (CON) (table 1, p=0.003). After 28 weeks of nicotine 
treatment, groups N60 and N100 had significantly lower serum creatinine 




(31±1 μmol/l and 32±2 μmol/l, both p<0.05) than the CON group. To certify 
that  
observed differences are the consequence of changes in kidney function and not 
changes in muscle mass, creatinine clearance was calculated. Nicotine 
treatment improved kidney function dose-dependently compared to CON 
(p=0.003) (figure 1A). Urinary protein excretion (UPE) increased 
spontaneously in MWF rats during the experiment, with values of 38 (22-57) 
mg/24h and 140  
(105-159) in the CON group at the end of the experiment (p<0.001). Nicotine 
treatment for 28 weeks reduced UPE compared to CON (p=0.03 all nicotine 
groups vs CON) (figure 1B). We further calculated the percentage reduction of 
24h UPE by nicotine treatment at end of the experiment ie after 28 weeks of 
nicotine treatment. The percentages are calculated as UPE decline in nicotine 
treated animals relative to the non nicotine treated control group. Although no  
impressive differences were achieved, nicotine treatment significantly mitigated 
rise in UPE by about 10%, 20% and 16% in the N20, N60 and N100 groups 
resp.  
 
Figures 1A and 1B 
 





Glomerular histomorphological analysis 
PAS staining was done to quantify GS. MWF rats developed de novo GS over 
time. At the end of the study, CON had higher GS than nicotine treated groups 
(p=0.001). Long term nicotine treatment led to a significant, approximately 
50% reduction in GS score in N60 and N100 vs CON (both p=0.02) (figure 2). 
Similarly podocyte loss and desmin positivity were higher in CON vs baseline 
(p= 0.04 and p=0.01 resp.). Long term nicotine treatment led to preserved 
podocin staining and lower desmin deposition (figure 3 and figure 4 resp.). 
 
Figure 2 (FGS)          Figure 3 (Podocin)  
  
 











Long term nicotine 
treatment led to a 
significant, approximately 
50% reduction in Desmin 
score in N60 and N100 vs 
CON (both p=0.01) 











Renal infiltration of monocyte/macrophages and myofibroblasts 
Nicotine treatment in N60 and N100 significantly reduced the amount of ED1 
positive macrophages in the kidney when compared to CON (p=0.001) (figure 
5). Myofibroblasts were stained with α-SMA and represent a major cell type 
involved in interstitial matrix deposition. Figure 6 shows that N60 (p=0.01) and 
N100 (p<0.05) had significantly reduced α-SMA positivity in the kidneys when 
compared to CON. 












































Since the influx of ED-1 positive monocytes and macrophages was reduced 
upon oral nicotine, we evaluated by qPCR renal expression of MCP-1 and 
VCAM-1, the former being a major chemo-attractant and the latter being an 
important adhesion molecule for monocytes and macrophages. Both, the 





expression of MCP-1 and VCAM-1 were higher in CON at the end of the study 
compared to baseline (both p<0.01, Figure 7A and 7B resp.). Nicotine treatment 
dose-dependently lowered the expression of total MCP-1 in N20, N60 and 
N100. However N60 (p<0.01 vs CON) and N100 (p<0.01 vs CON) reached 
statistically significance Moreover, nicotine treatment lowered the expression 





Our results demonstrate that long term oral nicotine improves renal function 
and morphology and reduces renal inflammation in the Munich-Wistar-Fromter 
rat. As anticipated in this model, the CON group developed loss of kidney 
function, GS and tubulo-interstitial inflammation. The glomerular as well as 
interstitial damage was reduced by oral nicotine in a dose dependent manner. 
Improvement was also seen at mRNA level by down regulation of the 
inflammatory markers MCP-1 and VACM-1.  
Nicotine and cigarette smoking have been shown to elicit an acute systemic 
adrenergic response, resulting in increases in blood pressure and heart rate in 




both healthy subjects and renal patients (37). It is, however, questionable 
whether these effects are sustained on the longer-term. In an animal study, the 
same group found no effects on blood pressure of long-term administration of 
nicotine in combination with cigarette smoke extract (38). Consistent with these 
findings, we did not find any statistical significant change in blood pressure in 
our long-term animal study. Whereas our assessment of blood pressure by tail-
cuff is not gold standard, it seems implausible that an effect on blood pressure 
would go unnoticed altogether.  
On one hand, nicotine is known to induce endothelial nitric oxide synthase 
(eNOS) which is vasodilatory in isolated perfused kidney (39) while on the 
other hand, it is known that that acute or chronic nicotine attenuates the renal 
vasodilatory responsiveness to some vasodilator pathways (40). Therefore, a 
direct effect on glomerular pressure either by efferent vasodilatation or afferent 
vasoconstriction can not be excluded, in particular because UPE was slightly 
higher in CON groups than in nicotine treated groups. The lowering of UPE 
was persistent throughout the experiment. This lowering in UPE might have 
contributed to the observed renoprotective effects of oral nicotine. 
It is known that nicotinic receptors are present on macrophages, peritubular 
capillaries, dendritic cells and vascular smooth muscle cells (21,27,41). 
Previous studies have shown that nicotine reduces monocyte/macrophage influx 
in tissues via the α-7NAchR pathway and reduces endothelial activation 
(30,42). Nicotinic agonists attenuate the activation of macrophages (43). We 
also showed that macrophage infiltration was reduced in nicotine treated 
animals. Various cytokines, including IFN-γ, IL-6 and lymphocyte activation, 
are implicated in the activation of macrophages (44,45). Nicotine is known to 
down regulate these inflammatory cytokines and this effect could play a role in 
reduction of glomerulosclerosis and interstitial fibrosis (29,46,47). We observed 
reduced glomerulosclerosis and lower density of myofibroblasts. These 
observations indicate an anti-fibrotic effect of nicotine. However, we cannot 
discriminate between a direct nicotinic anti-inflammatory effect and a 
secondary nicotinic effect via reduction in UPE. We investigated the 





therapeutic effects of oral nicotine in 3 different doses. There was clear 
reduction of GS, UPE, podocytopathy, desmin deposition, ED-1 influx and α -
SMA accumulation at N20 which is in between CON and N60. For 60 and 100 
except for α-SMA, the effects were more or less similar, suggesting that there is 
saturation of nicotinic receptors at and beyond 60 mg/l.  
Few studies have investigated the role of nicotine in rodent models of kidney 
disease. Although findings of our study are consistent with many studies, some 
studies even reported opposite results. On one hand, our findings are in line 
with findings of Yeboah et al and Sadis et al, where they found anti-
inflammatory effects of oral nicotine in rat models of I/R induced kidney 
damage (25,48). On the other hand, a deteriorating effect of nicotine was found 
in mice models for diabetes (49) and ischemia reperfusion injury (50). How 
might these differences been explained? First of all, it is always cumbersome to 
compare rodent models with respect to strain differences (mouse vs rat) and 
source of delivery, sex (male vs female), age, and dosage scheme of the drug. 
More importantly is to realize that effects of nicotine are evaluated in different 
models of renal disease. Our model, the MWF rat, is a proteinuric model (51). 
That means that proteinuria is the driving force behind renal damage. 
Proteinuria can be reduced by reducing glomerular pressure. Most likely, 
nicotine reduced glomerular pressure and/or reduced proteinuria, and 
consequently renal function and morphology and renal inflammation is 
reduced. The studies that reported negative effects of oral nicotine used diabetic 
mice and mice that underwent ischemia/reperfusion (45, 46). Driving forces 
behind renal damage in these models are hyperglycemia and lack of oxygen 
respectively, which apparently uses other activation and signalling routes that 
are less sensitive to interference with nicotine. Moreover, the MWF rat model 
used by us demonstrates more chronic inflammation compared to the db/db 
mice and the chronic phase of ischemia/reperfusion. This might explain why 
anti-inflammatory actions of nicotine were more clear in our model. 
Smoking is a risk factor for cardio-vascular diseases, kidney disease and lung 
cancer (13,52).  




Nicotine is one of the most addictive components of cigarette smoke. Our study 
indicates that oral nicotine besides reducing direct harmful effects from 
cigarette smoking and overcoming the addiction of smoking, reduces 
inflammation in kidneys. However nicotine binds to all nicotinic receptors and 
could lead to systemic side effects. Binding of nicotine to neural nicotinic 
receptors makes it addictive in nature. Caution should be taken in prescribing 
nicotine due to its potential cardiovascular side-effects. Further research is 
necessary to assess whether nicotine without concomitant exposure to other 
constituents normally present in cigarette smoke or carbon monoxide is harmful 
from a cardiovascular perspective (53,54). Thus, other specific α-7nAchR 
agonists could be of therapeutic use, particularly if these compounds would be 
devoid of addiction effects.  
To the best of our knowledge studies with long term nicotine are lacking 
despite nicotine being used chronically in clinical settings. Therefore we 
investigated nicotine usage in a long run and found that nicotine is reno-
protective in MWF rat model of spontaneous proteinuria. It should, however, be 
realized that these renoprotective effects may be limited to the model we used. 
MWF rats have spontaneous progressive proteinuria and glomerular 
podocytopathy (51,55). Therefore, it can not be excluded that similar beneficial 
effects are not present in other models of progressive proteinuria and kidney 
disease. This deserves additional experiments. The kidney function was 
measured with creatinine clearance so as to avoid any effects of change in 
muscle mass (56). We found that nicotine treatment improved creatinine 
clearance. However kidney function as measured by creatinine clearance is not 
the gold standard specially in rodents since there is a considerable amount of 
tubular secretion of creatinine. Measuring renal function with exogenous renal 
markers, such as inulin, iothalamate or iohexol, although considered to be the 
gold standard, is time consuming, invasive and cumbersome (57). We therefore 
cannot exclude the nicotine induced tubular secretion of creatinine in the 
nicotine treated animals. Our conclusion of renoprotective effects of nicotine 
however are based not solely on the improvement of creatinine clearance but 





also on the concomitant moderate attenuation of UPE and renal morphological 
improvements. Furthermore, although we show that oral nicotine results in 
lowering of proteinuria and renal inflammation, the exact mechanism 
responsible for renoprotection is not identified by our study and deserves 
further research, e.g. by further studies with renal denervation.   
 
In conclusion, our data show that long term oral nicotine improves kidney 
function, reduces proteinuria, renal inflammation and glomerulosclerosis in 
Munich-Wistar-Fromter rats. This novel action of nicotine could be evaluated 
as a potential additional therapeutic option for treating proteinuric and/or 
inflammatory kidney diseases. 
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Aims: Transplant vasculopathy (TV) is an important component of chronic 
allograft rejection. TV is associated with neointima formation. Inflammation 
plays a central role in the process of neointima formation. Nicotine is known to 
be anti-inflammatory in nature. We recently found indication that nicotine 
prevents neointima formation and aimed to investigate whether it could prevent 
neointima formation in another model of neointima formation.  
In a first experiment, we found neointima formation in intrarenal arteries in the 
hypertensive Munich-Wistar-Frömter rat model of spontaneous proteinuria. In 
this model, nicotine treatment with 60 mg/l and 100 mg/l drinking water 
reduced neointima formation by 90 % and 85 % respectively compared to non-
nicotine treated rats (both p<0.01 vs non-nicotine treated control rats). In a 
subsequent experiment, we aimed to evaluate whether nicotine treatment could 
prevent formation of TV in a rat renal allo-transplantation model. Similar to the 
findings of the first experiment, nicotine treatment (60 mg/l) reduced neointima 
formation by 79% compared to non-nicotine treated rats (p=0.055). Other 
physiological parameters like blood pressure and body weight remained 
comparable among groups in both the experiments.  
This study reports presence of neointima formation in intra renal arteries of a 
MWF rat model of spontaneous kidney disease and further demonstrates that 
nicotine reduces neointima in this model. Furthermore, nicotine tended to 
prevent neointima formation in a model of TV. Therefore we suggest to further 
investigate nicotine as an additional therapy for treatment of neointima 
formation which is commonly seen with transplant vasculopathy, to delay 










Transplant vasculopathy (TV) is an important component of chronic 
allotransplant rejection. TV is a complex process with poorly understood 
pathophysiology. A prominent histological feature of TV is neointima 
formation resulting from infiltration of inflammatory cells, proliferation of 
smooth muscle cells and accumulation of extracellular matrix (1,2). The end 
result is progressive luminal occlusion and end organ failure. Therefore long 
term graft survival can be improved by reducing neointima formation 
associated with TV. Various mechanisms have been proposed to understand the 
origin of neointima formation including changes in hemodynamics, disruption 
of endothelial barrier and ischemia reperfusion injury (3-6). Inflammation is, 
however widely argued to be a central event in the process of neointima 
formation, triggered by vascular injury and maintained through autocrine or 
paracrine mediators (7).  
Inflammation can be modulated via non-neuronal cholinergic pathway (8,9). 
The effects are thought to be mediated via nicotinic acetylcholine receptors 
(nAchRs), mainly α7-nAchR. Non neuronal α7-nAchR has been described to be 
present on macrophages as well as on endothelial cells (ECs) (10). Nicotine is 
non-specific agonist of nAchRs. The binding of nicotine to α7-nAchR is known 
to be anti-inflammatory (11,12). It has been shown that activation of nAchRs 
ameliorates diseases of inflammatory origin like ulcerative colitis and sepsis 
and ameliorates endothelial dysfunction (13-15). It has also been shown that 
nAchRs are down regulated in inflammatory conditions and nicotine 
pretreatment up regulate the nicotinic receptors (16). In a Munich-Wistar-
Frömter (MWF) rat model of spontaneously proteinuria, we have recently 
shown that long term nicotine ameliorates decline in kidney function and 
progressive renal structural damage (17). In this model, we observed neointima 
formation in intra-renal arteries and partial prevention of this formation in 
animals treated with nicotine. We hypothesized that nicotine treatment could 
also slow down the development of neointima formation in association with 
TV.  




The aims of this study are following: 1) to report presence of neointima 
formation in intra renal vessels of a MWF rat model of spontaneous kidney 
disease and effects of nicotine on the neointima formation. 2) To investigate 
effects of nicotine on neointima formation in a rat renal transplantation model 
of TV.  
  
Material and Methods 
Animals 
24-wk old Munich-Wistar-Fromter rats were obtained from Harlan (USA), 10 
wk male Wistar Furth rats were obtained from Harlan (Zeist, The Netherlands) 
and 10 wk female Dark Agouti rats were obtained from Charles River 
(Maastricht, The Netherlands). All animals were housed in temperature 
controlled 12h light/12h dark rooms and had free access to food and drinking 
water. All animals received human care in compliance with the Principles of 
Laboratory Animal Care (NIH Publication no. 85-23, revised 1996) and the 
protocols of both experiments were approved by Animal Ethical Committee of 
University of Groningen. 
 
Experiment 1: Spontaneously proteinuric MWF rat model 
Spontaneously proteinuric MWF rats (n=44) were used. Division of rats in 
different treatment groups have been previously described (17). Briefly for 
baseline renal vascular measurements MWF rats (n=6; Baseline) were 
sacrificed at week 24 of age. The other animals were randomly assigned to four 
different groups. Rats were given either of 3 different concentrations 20 mg/l 
(n=9; MWF20), 60 mg/l (n=9; MWF60) and 100 mg/l (n=10; MWF100) of 
nicotine mixed with 0.5% sodium saccharin as sweetening agent ad-libitum in 
drinking water. Rats in the control group (n=10; CON) only received water 
sweetened with 0.5% sodium saccharin. Animals were sacrificed after 28 weeks 
of treatment (i.e. at 52 weeks of age).  
 
 





Experiment 2: Kidney allo-transplantation model 
Left orthotopic kidney transplantation was carried out from female Dark Agouti 
(DA) rats to male Wistar Furth (WF) rats as previously described (18). Briefly 
kidneys from donor DA rats were flushed and stored in cold saline. Cold 
ischemia time ranged from 12-20 minutes. In recipient WF rats, renal vessels 
were clamped and the left kidney was removed. During surgery renal vein, 
artery and ureter were end to end anastomosed and vascular clamps were 
removed. Warm ischemia time of 25 min was kept constant during all the 
transplantations. Rats received standard analgesic, buprenofine (Temgesic) 0.01 
mg/kg, twice on the day of transplantation and once on the second day of 
transplantation. To prevent acute rejection recipients received cyclosporine A (5 
mg/kg/day; Sandimmune, Sandoz Pharma AG, Basel, Switzerland) 
subcutaneously for first 10 days post transplantation. The contralateral native 
(right) kidney of WF rats was removed at day 14, and the rats were followed till 
the end of experiment. 
Nicotine treated groups received either 30 mg/l (WF30; n= 10) or 60 mg/l 
(WF60; n= 10) of nicotine in drinking water ad libium throughout the 
experiment. Recipients received nicotine starting 2 days prior to transplantation 
to get acclimatized to nicotine. Control group (CNT) received no nicotine 
(n=10). Animals were sacrificed at 9±2 weeks (mean 63 days) after 
transplantation. 
 
Experimental procedures during the experiments and laboratory 
measurements  
Body weight was measured weekly. Blood pressure was measured by tail cuff 
method after appropriate training of the rats. Venous blood was withdrawn 
under isoflurane anesthesia in heparin-containing tubes and plasma was stored 
in -80 °C until analysis. 24-h urine was collected in metabolic cages and stored 
at – 20 °C until analysis. 24-h water and food intake were measured in the 
metabolic cages. Animals were sacrificed under isoflurane-induced general 
anesthesia by cutting the diaphragm and cardiac bleeding. Animals were 




flushed with 0.9% NaCl, kidneys were harvested and partly stored in -80 °C 
and partly fixed in 4% formalin followed by embedding in paraffin. 
Plasma creatinine and urinary protein were measured by multi-test analyzer 
system (Roche Modular; F. Hoffmann-La Roche Ltd, Basel, Switzerland). 24-h 
urinary protein excretion was calculated from urinary protein concentration and 
24-h urinary output. 
 
Morphometric analysis of renal vessels 
4 μm thick formalin fixed paraffin sections were deparaffinized and were 
stained with Verhoeff’s Masson staining. With this staining the internal elastic 
lamina (IEL) and external elastic lamina (EEL) were stained in black and the 
interstitial tissue was stained in red.  
In every rat, in a blinded fashion, all the identifiable elastin positive intra renal 
vessels were evaluated for luminal diameter, neointima area and medial area 
using Olympus BX50 research microscope and Cell^B Olympus programme 
(Olympus Europe, Hamburg, Germany). Diameter of vessels calculated as the 
mean length of two straight lines drawn from IEL and passing through the 
center of vessel. The areas enclosed by lumen, IEL and EEL were measured. 
The area between the lumen and IEL was described as neointimal (NI) area and 
the area enclosed between IEL and EEL was described as medial area. The ratio 
between NI area and medial area was calculated. [NI area (if present)/ area 
enclosed by IEL] X 100 is described as percentage of luminal occlusion.  
 
Statistical analyses 
Statistical analysis was performed using Spss 14. Figures were made using 
GraphPad Prism (version 4.00; GraphPad Software, Inc., San Diego, CA). 
Differences among the groups were analyzed using ANOVA with Tukey post 
hoc. Differences between start of the experiment and end of the experiment 
were analyzed using independent samples t-test. Log rank test was used to test 
survival differences among groups. P < 0.05 was considered statistically 
significant.  







Survival and other physiological parameters of animals 
One animal in N60 was sacrificed prematurely because of tooth malformation 
due to which the animal was unable to eat and lost weight. One animal in N20 
was sacrificed because of a bone tumor. The tumor formation is unlikely to be 
related to nicotine since it was a sporadic case which might be related to aging. 
Both the animals were excluded from all analyses.  





Clinical parameters of spontaneous proteinuric MWF rat model and renal allo-
transplantation model. 










Figure 1: (Representative 
photos of vascular lesions) 
Representing intral renal 
artery from each group is 
depicted in figure 1. At the 
age of 24 weeks none of 
intra renal arteries in MWF 
rats had presence of 
neointima. In the animals at 
52 weeks of age, significant 
neointima formation was 
present in rats not treated 
with nicotine. The 
percentage of vessels 
affected with neointima was 
reduced in nicotine treated 
animals compared to non-
nicotine treated animals 
(figure 2A). Results for 
presence of neointima 
(figure 2B), neointima to 
media ratio (figure 2C) and 
luminal occlusion (figure 
2D) were consistent. Renal 
diameter was comparable among the non-treated control animals and the 










Figure 2 (quantification of vascular lesions of long term nicotine experiment) 
 






Survival and other physiological parameters of animals 
This experiment included 30 male WF recipients. During follow-up from 2-9 
weeks, pre-term graft failure occurred in 3 rats (30%) in CNT group , in 4 rats 
(40%) in WF30 group, and in 6 rats (60%) in WF60 group. The survival of 
animals in different groups is depicted by Kaplan-Meier curves in figure 3. The 
rats that were sacrificed before the end of the experiment (before 9 weeks after 
transplantation) were excluded from all analyses. Renal parameters (serum 
creatinine and creatinine clearance) of the excluded animals were comparable 
among the groups (data not shown). Accordingly, the analyses were performed 
with 17 rats i.e. CNT (n=7), WF30 (n=6) and WF60 (n=4). 
The physiological parameters are summarize in table 1.  
 
Figure 3 



































Morphometric analysis of renal vessels 
Representing intra renal artery from each group is depicted in figure 4. The 
percentage of vessels with neointima formation was reduced in 60 mg/l nicotine 
treated animals compared to non-nicotine treated animals (figure 5A). The 
reduction of neointima in 60 mg/l nicotine group was borderline significant 
when compared to control group (p=0.055) (figure 5B). There was trend 
towards reduction of the neointima to media ratio in 60 mg/l nicotine groups 
when compared to non-nicotine treated control group (figure 5C). The ratio 
between neointimal area and total lumen area represents the percentage of 
occlusion. The nicotine treatment with 60 mg/l and reduced the luminal 
occlusion compared to non-treated group by 50% (figure 5D). The renal 
diameter was comparable among the non-treated control animals and the 
nicotine treated animals (figure 5E). 
 
Figure 4 (Representative photos of vascular lesions) 
 





Figure 5 (quantification of vascular lesions of transplantation experiment) 
 
  





In this study we describe that nicotine treatment reduces neointima formation in 
intra renal arteries in two different rat models renal disease with neointima 
formation. The specific effect of nicotine on intra renal artery neointima 
formation is independent of change in blood pressure.  
Transplant vasculopathy is an important component of chronic transplant 
dysfunction. The pathophysiology of neointimal lesions is unclear, therefore 
poses great difficulties in designing appropriate therapy. However endothelial 
cell activation and inflammatory process play a crucial role in pathways leading 
to progression of neointima formation (19). Therefore therapies targeting those 
routes might prove to be promising.  
In a rat model of spontaneously proteinuria (experiment 1) we observed the 
presence of neointima in intr-renal arteries. The presence of neointima 
formation in the MWF rat model has not been described previously. In this 
study we therefore report the finding. Additionally we found that neointima 
formation was ameliorated by nicotine treatment where higher dose nicotine 
treated animals had lesser formation of neointima. It was therefore suggestive 
that nicotine is arterio-protective. 
This finding led us to investigate nicotine effects on a rat model of TV in the 
setting of kidney transplantation. In this experiment investigation with 2 
different concentrations of nicotine (30 mg/l and 60 mg/l) were carried. The 
concentrations were chosen based on observation from experiment 1 that 
nicotine effects were comparable at concentrations 60 mg/l and 100 mg/l. 
Neointima formation in kidney transplantation contribute to chronic transplant 
dysfunction (CTD), thus therapies aiming at reducing transplant vasculopathy 
are clinically relevant. We thus investigated nicotine effects in an orthotopic 
allo-transplantation model from female Dark Agouti into male Wistar Furth rats 
(18). The allo-transplanted animals developed renal function decline along with 
systemic hypertension. The transplanted kidney showed signs of CTD like 
glomerulosclerosis, interstitial fibrosis, tubular atrophy, and transplant 
vasculopathy with neointima formation. Neointima formation was characterized 





by concentric intimal hyperplasia with luminal occlusion. Nicotine treatment in 
the highest dose showed a clear tendency towards reduction in amount of 
neointima. We however did not find any reduction in proteinuria, however a 
tendency of improvement in kidney function was observed, which did not reach 
statistical significance, probably related to a small number of animals in 
nicotine treated groups resulting in a statistical power problem. 
Nicotine effect on vessels has been previously studied. Rodella et al used 
nicotine treatment as model for neointima formation while aiming to investigate 
anti-oxidant properties of melatonin (20). They found that nicotine treatment 
for 56 days induced neointima formation in aorta. Vazquez-Padron et al showed 
that VSMC proliferation plays an important role in neointima formation in 
injured right Iliac-artery of rats pretreated with nicotine (21). In the study by 
Vazquez-Padron et al the nicotine treated rats developed hypotension which is 
in contrast to our model. Hypotension related hypoxia might be an inducible 
factor for nicotine associated effect of neointima formation, although we did 
not find effects of nicotine on blood pressure. Hamasaki et al concluded that 
administration of nicotine tend to accelerate the intimal hyperplasia upon 
removal of the endothelial lining (22). At present we cannot explain why 
neointima formation in aforementioned studies is increased by nicotine, while 
we find protective effects in two independent rat renal models of kidney 
disease. It might be that the smaller renal arteries (ranging from 50-250 um) 
responds differently from larger arteries of the body. Besides to that, both renal 
models are characterized by increased blood pressure, which might influence 
nicotine effects. Additionally dose of nicotine, duration of treatment or 
induction of neointima by mechanical or non-mechanical injury might be 
associated with the different findings. Though we did not aim to study the 
mechanism of action of nicotine effects on neointima formation but anti-
inflammatory action of nicotine might well play a role. Nicotine is known to be 
anti-inflammatory acting mainly via α7nAchRs (23,24). α7nAchRs are present 
on monocytes and vascular endothelium, and also on vascular smooth muscle 
cells and fibroblasts (8,25,26). Agonists of nicotinic receptors inhibits 




activation of monocytes and endothelial cells. We have also shown lower influx 
of monocytes/macrophages in interstitium of nicotine treated MWF rats (17). 
Therefore it might be that nicotine inhibited monocyte activation leading to 
slower progression in neointima formation. However this requires further 
investigation with nicotinic receptor knock out models.  
Another key player for nicotine related effects might be nitric oxide (NO). 
Vascular integrity is necessary to maintain normal functioning of blood vessels. 
Under healthy conditions the integrity is maintained by secreted NO from intact 
endothelium (27). The endothelium lining gets damaged in transplantation 
setting and under conditions of high blood pressure. It has been shown that 
supplementation with exogenous NO can repair the damaged vascular integrity 
(28,29). nAchRs are present on endothelium and nicotinic agonists are known 
to induce eNOS production and secretion and increase formation and secretion 
of NO from endothelial cells. NO causes vasodilatation, decreases SMC 
activation and proliferation thus inhibit progression of neointima formation 
(30). nAchRs are also shown to present on macrophages. Agonists of such 
receptors lead to inhibition of monocytes activation, lesser chemo-attractant 
secretion which is required to sustain inflammation and reduced proliferation of 
VSMCs. Moreover local chemoattractant properties of macrophages may be 
reduced by nicotine. Recent studies with drug eluting stents which deliver NO 
also showed to be beneficial in preventing in stent restenosis after traumatic 
injury, are line with our finding (3).  
In this study we describe that nicotine reduces progressive neointima formation 
in two different rat models of renal neointima formation. However there are few 
limitations of the study. Like in all animal studies the results of the study should 
be interpreted with caution when relating to human pathology. Because of the 
full HLA mismatch between the donor and recipient in experiment 2 there was 
severe damage to the transplanted kidney, resulting in a high number of 
dropouts in all the groups. Although the drop-out rate was not significantly 
different among the groups, most rats dropped out in the highest (60 mg/l) 
nicotine group. However in experiment 1 the same dose (60 mg/) and a higher 





dose (100 mg/l) were well tolerated. Besides to that, in experiment 2 we cannot 
exclude a certain selection bias in the surviving animals. Lastly, the resulting 
low number of animals that were included in the analyses of experiment 2 
raised a power problem for proper statistics. 
In summary, we describe that nicotine treatment reduce the amount of renal 
neointima formation in two different rat models of renal neointima formation. 
We suggest to further investigate nicotine as an additional therapy for treatment 
of neointima formation, to delay progressive decline of renal function and 
chronic transplant dysfunction in renal allo-transplantation.  
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General Discussion and Future Perspective 




Summary and general discussion 
The studies presented in this thesis aimed to explore the effects of smoking and 
nicotine on the kidney. Diabetes, hypertension and obesity are well established 
risk factors for cardiovascular and renal diseases (1-6). Association between life 
style related risk factors and kidney diseases is now also being recognized. 
Potential roles of salt intake, physical activity, sleep, and psychosocial stress on 
the progression of chronic kidney disease (CKD) are increasingly being 
evaluated (7-12). Despite the development of newer therapeutic modalities and 
improved patient management, many patients still progress to End Stage Renal 
Disease (ESRD) which necessitates renal replacement therapy (13-15). 
Therefore, it is important to identify new risk factors, specially those which are 
modifiable, to develop new intervention strategies. Smoking is a modifiable 
risk factor associated with cardiovascular diseases and with progression of 
diverse kidney diseases, like diabetic nephropathy, IgA nephropathy, 
hypertensive kidney disease and so forth. In the same line of research, in this 
thesis we investigated effects of smoking on native and transplanted kidneys.  
 
Smoking and deterioration of kidney function 
Smoking has recently been identified as a risk factor for development and 
progression of chronic kidney disease in native kidneys (16-18). Cigarette 
smoking can cause renal damage by causing renal vasoconstriction, thus 
eliciting a decline in effective renal plasma flow, by toxic effects from 
oxidative components and by exposure to heavy metals (19-25). Nicotine is one 
of the main components of cigarette smoke. Nicotine is also thought to be 
injurious to the kidneys (26-29). One of the contemporary theories is that 
detrimental effects of smoking on kidneys is through the action of nicotine on 
the sympathetic nervous system, thereby inducing intrarenal vasoconstriction 
and parenchymal ischemia (22,30,31). It should be noted that the kidneys of 
renal transplant recipients receive no innervation. If kidneys of renal transplant 
recipients would be susceptible to detrimental effects of smoking, it would be 
an indication that mechanisms other than an effect of nicotine on the 





sympathetic nervous system are involved. In chapter 2 of this thesis we 
therefore set out to investigate the association of cigarette smoking on decline 
in kidney function and development of graft failure in renal transplant 
recipients (RTR). We found that in current smokers the decline in kidney 
function was faster than that in past and never smokers, with similar slower 
rates of decline for past and never smokers. In line with this, we found that 
current smokers had a higher risk for development of graft failure than non-
smokers or ever smokers. If nicotine related sympathetic activation was a cause 
of the nephrotoxic effects of smoking, such an effect would not have been 
observed in the RTR model of renal denervation. Therefore it is suggestive that 
mechanisms other than nicotine induced sympathetic hyper-activation are 
involved. 
As smoking is a main disease progression factor in chronic pulmonary 
disorders, many patients that require a lung transplant have a history of heavy 
smoking. Approximately 60% of lung transplant recipients have a history of 
smoking (32). However, they have to stop smoking before being considered for 
transplantation. In most lung transplant recipients renal function deteriorates 
progressively after transplantation, often resulting in CKD (33), with a likely 
role for CNI toxicity, superimposed on the frequently occurring bout of 
hypotension-elicited AKI in the early post-operative phase. Therefore CKD is 
being recognized as a serious complication after lung transplantation (34). 
Progression from CKD to end-stage renal disease (ESRD) requiring renal 
replacement therapy develops in 3-10% of lung transplant recipients (35-37). 
This population is therefore relevant to investigate the effects of former 
smoking on the kidney, although other factors such as CNI toxicity are involved 
in the renal damage in this population as well. 
It seems likely that cigarette smoking may induce a direct noxious effect, e.g. 
through induction of systemic oxidative stress that persists for years. For 
toxicants present in cigarette smoke to exert a direct noxious effect on the 
kidney, these toxicants should be able to enter the circulation and reach the 
kidney. Kidneys being highly metabolically active might be susceptible to the 




toxic compounds present in the cigarette smoking. Recently it was found that 
smoking induced changes in epigenetics of megakaryocytes which are the 
precursors of platelets can persist for more than 10 years after smoking 
cessation, showing that late effects of smoking can last for many years (38,39). 
These findings are corroborated by data of persisting increases in risk of 
smoking-associated conditions long after cessation of smoking. For instance, 
the risk of lung cancer remains increased 15-fold in men and 9-fold in women 
at least until ten years after smoking cessation (40-42).Cigarette smoke consists 
of many components. Broadly they could be classified as hydrophilic, lipophilic 
or amphiphilic. It is known that lipophilic cigarette smoking components reach 
the distant organs like liver and kidneys (43). Additionally tobacco in cigarettes 
are rich in heavy metals like Arsenic, Lead, Mercury or Cadmium (44,45). The 
toxic components in cigarette smoke can lead to DNA damage and accelerate 
apoptosis (23). It has indeed been demonstrated that intra-renal vascular 
pathology (myo-intimal hyperplasia, arteriolar hyalinosis, glomerular sclerosis) 
in renal biopsies of former-smokers is more prominent than in never smokers 
without apparent difference in renal function (46). Thus, renal damage related 
to prior smoking can be present in the kidney after smoking cessation without 
being reflected in kidney function. Therefore a lung transplantation population 
is of interest in terms of mechanisms by which smoking could be detrimental 
for the kidney. If a sympathetic nervous system mediated vaso-constrictive 
effect of nicotine on renal nerves would play a role in a potential association of 
smoking with renal disease, one would not expect a long term association of 
former smoking with the renal risk in these patients. If, however, the effect is 
mediated by other toxic effects, former smoking could be associated with renal 
disease in these patients. In chapter 3 of this thesis we therefore set out to 
evaluate the effects of past smoking on development of CKD in a lung 
transplantation population. We found a dose dependent association of cigarette 
smoking with the development of various stages of CKD, with higher the 
number of pack-years of cigarette smoking, the more rapid the progression 
towards higher stages of CKD. The association of former cigarette smoking 





with the development of various stages of CKD was independent of other 
known renal risk factors. This observation is another plea against the theory that 
the detrimental effect of smoking on kidneys is through an effect of nicotine on 
the sympathetic nervous system, although this should be interpreted in the 
context of the complex pathogenesis of progressive renal function loss after 
lung transplantation.  
 
Smoking, alcohol consumption and all-cause mortality 
Smoking is unequivocally detrimental, while low amounts of alcohol intake are 
usually considered beneficial. Nevertheless, smoking and alcohol intake often 
go together (47). We found a positive association of smoking with alcohol 
intake in our study on smoking in RTR (chapter 2). Therefore we sought out to 
investigate the effect of alcohol intake in RTR. It appeared that little was 
known about alcohol consumption in RTR. The studies that were available 
indicated that pre-transplant alcohol addiction was associated with early graft 
failure, but no prospective studies had been performed on the potential 
association of continued alcohol consumption after transplantation and long-
term outcome (48-50). In chapter 4 of this thesis we therefore investigated the 
association of smoking with alcohol consumption in RTR on one hand and the 
influence of smoking and alcohol consumption on graft failure and all-cause 
mortality on the other hand. We found that smoking was positively associated 
with alcohol intake. We also found a beneficial effect of moderate alcohol 
consumption on mortality and new onset diabetes after transplantation 
(NODAT) in RTR, particularly if we took the detrimental effect of smoking 
into account. Importantly, NODAT is now being recognized as a well-
established entity and receiving increasing attention in transplantation 
medicine(51), in particular because NODAT limits patient survival. The 
mechanism by which moderate alcohol induces protection is not known. 
Alcohol might act as a free radical scavenger and therefore anti-oxidative. 
Antioxidants render protection against arteriosclerosis, reduce peripheral 
insulin resistance and beneficial for pancreatic beta cells. Moreover, these 




conditions are associated with inflammation. Alcohol containing beverages for 
example red wine is known to contain various anti-oxidants which might 
improve the overall mortality by reducing inflammation. Moreover alcohol 
consumption is associated with “feel good feeling” which might also indirectly 
influence the outcome. Resveratrol present in wine is a well-known anti-oxidant 
and anti-aging compound, and therefore could influence the outcome in RTR. 
Another underlying mechanism could be by beneficial effects on lipid profile 
with decreased low density lipoprotein, increased high density lipoprotein or 
reduced oxidized low density lipoprotein (52). However, since the majority of 
our population used statins, it is difficult to assess an independent effect of 
alcohol on lipid profile, and therefore, this should be subject of future research. 
 
Nicotine and progressive renal failure  
Cigarette smoke contains many compounds. Among them nicotine is one of the 
most abundant and an addictive component (53). Nicotine is used in different 
forms to quit smoking, also by renal patients (54). Nicotine acts through 
nicotinic receptors (nAchR). Among the nicotinic receptors the α7nAchR is 
widely studied and most described. Agonists of this receptor shows anti-
inflammatory properties (55-58). Nicotine is shown to be beneficial in diseases 
with inflammatory components like inflammatory bowel disease, multiple 
sclerosis and rheumatic arthritis. Acute experiments showed impact of nicotine 
on renal hemodynamics: exposure to 4-mg nicotine gum (about 2 mg would be 
absorbed) in non- smokers significantly increased (8±1 mmHg) mean arterial 
pressure (MAP), whereas estimated renal plasma flow (ERPF) and GFR 
decreased by 15±4% and 14±4% respectively. In habitual smokers the same 
nicotine exposure increased MAP similarly but ERPF and GFR remained 
unchanged. The virtual absence of renal effects of acute nicotine administration 
in in smokers were ascribed to dramatic 87% increase in urinary cyclic GMP 
after nicotine administration. Nicotine had not changed urine volume or sodium 
excretion in either group (59). Similar effects of 6-mg nicotine gum on BP and 
GFR was observed by Ritz (31). It is, however, questionable whether these 





effects are sustained on the longer-term and it is unclear whether this translates 
into effects on renal morphology and modification of processes of renal 
damage. To assess the effects of long term nicotine administration on the 
progression of renal disease, therefore, in chapter 5 we evaluated the effects of 
long term oral nicotine in a rat model of kidney disease. Nicotine treatment 
slightly reduced UPE with amelioration of structural damage compared to non -
nicotine treated control rats. Remarkably, nicotine treatment reduced 
glomerulosclerosis, tubulo-interstitial inflammation and fibrosis. Thus, though 
nicotine was thought to be the “nephrotoxic” component of cigarette smoke, 
our results suggest nicotine to be “renoprotective”. This might be clinically 
relevant, as, first, nicotine is frequently used in quit-smoking programs, and 
second it could be considered as an adjunct renoprotective intervention. 
However, before nicotine could be considered as an additional renoprotective 
measure in clinical practice, many hurdles have to be overcome. First of all, 
there is its addictive effects. Furthermore, caution should be taken in 
prescribing nicotine due to its potential cardiovascular side-effects. Further 
research is therefore necessary to assess whether nicotine without concomitant 
exposure to other constituents normally present in cigarette smoke is harmful 
from a cardiovascular perspective (60,61). However, it is tempting to speculate 
that other specific α-7nAchR agonists, devoid of addictive effects, could be of 
therapeutic use.  
 In the study we did not unravel the mechanism of nicotine action. There are a 
number of possible explanations for our findings. We found an anti-
inflammatory action of nicotine – as apparent from reduced renal influx of 
inflammatory cells, but others have also reported action of nicotine on intra 
renal vessels. It might be possible that nicotine reduced trans-glomerular 
pressure and thereby reduced the glomerular damage. On one hand, nicotine is 
known to induce endothelial nitric oxide synthase (eNOS) which is vaso-
dilatory in isolated perfused kidney (62) while on the other hand, it has been 
shown that nicotine attenuates the renal vaso-dilatory responsiveness to some 
vasodilator pathways, particularly when in combination with cyclosporine (63). 




Therefore, a direct effect on glomerular pressure either by efferent 
vasodilatation, or by afferent vasoconstriction or by a combination of both 
cannot be excluded, in particular because UPE was slightly higher in CON 
groups than in nicotine treated groups. Macrophage and endothelial cells are 
crucial players of inflammation . Nicotine receptors have been shown on these 
types of cells (57,64,65). It might be that nicotine directly reduces activation of 
monocytes and endothelial cells, but reduced intrarenal inflammation could also 
be secondary to the reduction in proteinuria. Future research therefore is needed 
to elucidate the mechanisms of reno-protective effects of nicotine.  
 
Nicotine and reno-vascular neointima formation 
In chapter 6 of this thesis we evaluated the role of oral nicotine on neointima 
formation in two different rat models of progressive kidney disease. By 
serendipity we observed presence of neointima in intra renal arteries of one-
year old Munich-Wistar-Fromter rats. Nicotine treatment for 28 weeks reduced 
the amount of neointima formation. Impact of nicotine on neo-intima formation 
had been described in models of primary vascular damage, thus rendering 
credibility to our data, that are, however, the first to shown an effect of nicotine 
on neo-intima formation in intrarenal vessels, in the context of renal disease. 
Since the finding of neointima formation in this rat model for renal disease was 
not previously described, and the effect of nicotine on renal neointima 
formation was new as well, we further tested the effect of nicotine in an 
experimental model of renal transplantation. In both the rat models we found 
that nicotine treatment reduced neointima formation. The second model, being 
a transplantation model, is devoid of any innervation. Our data therefore 
suggest that intact innervation is not necessary for nicotine mediated effects on 
neointima formation. There are a number of possible ways by which nicotine 
could modulate neointima formation. Nicotinic receptors are present on the 
endothelial cells as well as the macrophages (57,64,65). Both cells types play 
crucial roles in neointima progression. Nicotine action via such cells might 
slow down the progression of neointima formation. However, other cellular 





components might also play important roles in the process of neointima 
formation. For example, vascular smooth muscle cells present in the medial 
layer of vessels are also important for neointimal growth. It has been shown 
that vascular smooth muscle cells migrate to the sub-endothelial space and 
achieve a myofibroblast like phenotype and produce excessive extra-cellular 
matrix present in the neointima. Nicotine might interfere with migration, 
proliferation or apoptosis of smooth muscle cells. Nicotine is a known pro-
angiogenic factor (66). In addition to angiogenesis, nicotine increases 
expression of matrix metalloproteinases (67) and in such way may potentially 
ameliorate some forms of neointima formation. Additionally various cytokines 
secreted from endothelial cells and macrophages are involved in the process of 
neointima progression. Nicotine might also interfere with synthesis and 
secretion of such cytokines therefore reducing the downstream actions on 
vascular smooth muscle cells. However further research is required to elucidate 
the mechanisms involved.  





In this thesis we described that cigarette smoking is associated with rapid 
decline in kidney function in transplantation populations and that the effects 
persist long after quitting smoking. We furthermore found indications in an 
animal experimental model that nicotine is renoprotective.  
Cigarette smoke contains >100 chemical compounds and many of them are 
toxic (68-70). Based on their affinity to water or lipid they could be either 
hydrophilic (lipophobic) or hydrophobic (lipophilic) or amphiphilic. Animal 
experiments to investigate harmful components present in cigarette smoke 
could be carried out with the help of smoking machine. Such experiments will 
generate knowledge about pathological components present in cigarette smoke, 
and will potentially lead to more knowledge about environmental 
nephrotoxicants (heavy metals, for example) and mechanisms of kidney 
damage. After being exposed to cigarette smoke and different subclasses of 
smoke components, kidneys could be analyzed for presence of different 
cigarette smoking components. Furthermore deposition of cigarette components 
could be analyzed in separate kidney compartments using staining or high 
performance liquid chromatography (HPLC). Additionally in-vitro experiments 
could be carried out with these components of cigarette smoke on proximal 
tubular epithelial cells and glomerular endothelial cells. Of note, oral nicotine 
had renoprotective effects, rather than deleterious effects. This is an 
encouraging finding taking into consideration that nicotine is often used in quit 
smoking programs. Accordingly, our finding could also be translated to human 
studies with renal vascular function measurements in subjects following a quit 
smoking program with oral nicotine, for example. 
The mechanism of action of nicotine is not yet clear. We found that nicotine is 
protective in rat models of kidney disease. This effect could be because of 
cholinergic modulation of renal innervation, and/or via down-modulation of 
activation of non-neuronal cells such as endothelial cells and macrophages 
which are also inherently present in kidneys. To evaluate role of cholinergic 
nervous system on nicotine mediated renal effects further future experiment 





should be carried out with animals which are selectively devoid of renal 
innervation. In-vitro experiments could be carried out to investigate effects of 
nicotine on proliferation, apoptosis and migration of vascular smooth muscle 
cells and of endothelial cells. Additionally renal specific knock-out (KO) 
animal models of specific nAchRs should be created. Further studies with such 
KO models will be useful in describing roles of different nAchRs in kidney in 
association with nicotine. The receptors could specifically be targeted as a 
potential therapy for treatment of kidney diseases.  
Taken together the previous studies and the studies presented in this thesis 
demonstrate that the renal effects of nicotine are dissociated from those of 
smoking, with an overall beneficial effect of nicotine as opposed to the 
deleterious effects of smoking. This provides interesting perspective for future 
research to evaluate potential the beneficial effects of nicotine in kidney disease 
patients. 





(1) Boerner BP, Shivaswamy V, Desouza CV, Larsen JL. Diabetes and cardiovascular disease 
following kidney transplantation. Curr Diabetes Rev 2011 Jul 1;7(4):221-234.  
(2) Rakel A, Karelis AD. New-onset diabetes after transplantation: risk factors and clinical 
impact. Diabetes Metab 2011 Feb;37(1):1-14.  
(3) Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal 
lesions of chronic nephropathies and diabetes. J Clin Invest 2006 Feb;116(2):288-296.  
(4) Hanratty R, Chonchol M, Miriam DL, Beaty BL, Estacio RO, Mackenzie TD, et al. Incident 
chronic kidney disease and the rate of kidney function decline in individuals with hypertension. 
Nephrol Dial Transplant 2010 03;25(1460-2385; 0931-0509; 3):801-807.  
(5) Barri YM. Hypertension and kidney disease: a deadly connection. Curr Hypertens Rep 2008 
Feb;10(1):39-45.  
(6) Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated 
with underweight, overweight, and obesity. JAMA-J Am Med Assoc 2007 NOV 
7;298(17):2028-2037.  
(7) Thijssen S, Kitzler TM, Levin NW. Salt: Its role in chronic kidney disease. J Renal Nutr 
2008 JAN;18(1):18-26.  
(8) Thomas MC, Moran J, Forsblom C, Harjutsalo V, Thorn L, Ahola A, et al. The Association 
Between Dietary Sodium Intake, ESRD, and All-Cause Mortality in Patients With Type 1 
Diabetes. Diabetes Care 2011 APR;34(4):861-866.  
(9) Chou Y, Lee P, Yang C, Lin C, Veasey S, Chuang L, et al. Obstructive sleep apnoea: a 
stand-alone risk factor for chronic kidney disease. Nephrology Dialysis Transplantation 2011 
JUL 2011;26(7):2244-2250.  
(10) Roumelioti M, Buysse DJ, Sanders MH, Strollo P, Newman AB, Unruh ML. Sleep-
Disordered Breathing and Excessive Daytime Sleepiness in Chronic Kidney Disease and 





Hemodialysis. Clinical Journal of the American Society of Nephrology 2011 MAY 
2011;6(5):986-994.  
(11) Chen P, Huang Y, Kao Y, Chen J. Effects of an exercise program on blood biochemical 
values and exercise stage of chronic kidney disease patients. The journal of nursing research : 
JNR 2010 2010-Jun;18(2):98-107.  
(12) Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P. Sodium Intake, ACE 
Inhibition, and Progression to ESRD. J Am Soc Nephrol 2012 Jan;23(1):165-173.  
(13) Khouri Y, Steigerwalt SP, Alsamara M, McCullough PA. What is the Ideal Blood Pressure 
Goal for Patients with Stage III or Higher Chronic Kidney Disease? Curr Cardiol Rep 2011 Sep 
2.  
(14) Hanratty R, Chonchol M, Havranek EP, Powers JD, Dickinson LM, Ho PM, et al. 
Relationship between Blood Pressure and Incident Chronic Kidney Disease in Hypertensive 
Patients. Clin J Am Soc Nephrol 2011 Sep 15.  
(15) Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Predictors of new-onset 
kidney disease in a community-based population. Jama-Journal of the American Medical 
Association 2004 FEB 18 2004;291(7):844-850.  
(16) Maeda I, Hayashi T, Sato KK, Koh H, Harita N, Nakamura Y, et al. Cigarette smoking and 
the association with glomerular hyperfiltration and proteinuria in healthy middle-aged men. 
Clin J Am Soc Nephrol 2011 Oct;6(10):2462-2469.  
(17) Yamamoto R, Nagasawa Y, Shoji T, Iwatani H, Hamano T, Kawada N, et al. Cigarette 
smoking and progression of IgA nephropathy. Am J Kidney Dis 2010 Aug;56(2):313-324.  
(18) Stengel B, Couchoud C, Cenee S, Hemon D. Age, blood pressure and smoking effects on 
chronic renal failure in primary glomerular nephropathies. Kidney Int 2000 Jun;57(6):2519-
2526.  




(19) Odoni G, Ogata H, Viedt C, Amann K, Ritz E, Orth SR. Cigarette smoke condensate 
aggravates renal injury in the renal ablation model. Kidney Int 2002 06;61(0085-2538; 0085-
2538; 6):2090-2098.  
(20) Orth SR, Ritz E. The renal risks of smoking: an update. Curr Opin Nephrol Hypertens 
2002 09;11(1062-4821; 1062-4821; 5):483-488.  
(21) Orth SR, Odoni G, Ogata H, Ritz E. Smoking as a risk factor for end-stage renal failure in 
patients with primary renal disease. Contrib Nephrol 2000;130(0302-5144; 0302-5144):109-
123.  
(22) Benck U, Clorius J, Zuna I, Ritz E. Renal hemodynamic changes during smoking: effects 
of adrenoreceptor blockade. Eur J Clin Invest 1999 DEC;29(12):1010-1018.  
(23) Ueno S, Kashimoto T, Susa N, Ishikawa M, Kawagoe T, Mizuta K, et al. Smoking induces 
bimodal DNA damage in mouse lung. Toxicol Sci 2011 Apr;120(2):322-330.  
(24) Johri N, Jacquillet G, Unwin R. Heavy metal poisoning: the effects of cadmium on the 
kidney. Biometals 2010 Oct;23(5):783-792.  
(25) Telmer S, Christiansen JS, Andersen AR, Nerup J, Deckert T. Smoking habits and 
prevalence of clinical diabetic microangiopathy in insulin-dependent diabetics. Acta Med Scand 
1984;215(0001-6101; 1):63-68.  
(26) Arany I, Grifoni S, Clark JS, Csongradi E, Maric C, Juncos LA. Chronic nicotine exposure 
exacerbates acute renal ischemic injury. Am J Physiol Renal Physiol 2011 Jul;301(1):F125-33.  
(27) Hua P, Feng W, Ji S, Raij L, Jaimes EA. Nicotine worsens the severity of nephropathy in 
diabetic mice: implications for the progression of kidney disease in smokers. Am J Physiol 
Renal Physiol 2010 Oct;299(4):F732-9.  
(28) Jaimes EA, Tian RX, Joshi MS, Raij L. Nicotine augments glomerular injury in a rat 
model of acute nephritis. Am J Nephrol 2009;29(1421-9670; 4):319-326.  





(29) Benowitz NL. Toxicity of nicotine: implications with regard to nicotine replacement 
therapy. Prog Clin Biol Res 1988;261(0361-7742):187-217.  
(30) Orth SR, Viedt C, Ritz E. Adverse effects of smoking in the renal patient. Tohoku J Exp 
Med 2001 05;194(0040-8727; 0040-8727; 1):1-15.  
(31) Ritz E, Benck U, Franek E, Keller C, Seyfarth M, Clorius J. Effects of smoking on renal 
hemodynamics in healthy volunteers and in patients with glomerular disease. J Am Soc Nephrol 
1998 Oct;9(10):1798-1804.  
(32) Christiansen E, Madsbad S. [Smoking and diabetes mellitus]. Ugeskr Laeger 1989 
11/13;151(0041-5782; 46):3050-3053.  
(33) Cooper RG. Renal function in male rats concurrently exposed to nicotine & ethanol. Indian 
J Med Res 2007 06;125(0971-5916; 6):791-793.  
(34) Hellemons ME, Bakker SJ, Postmus D, Verschuuren EA, Erasmus ME, Navis G, et al. 
Incidence of impaired renal function after lung transplantation. J Heart Lung Transplant 2011 
Oct 4.  
(35) Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of 
Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant 
2008 11;8(1600-6143; 11):2243-2251.  
(36) Luan FL, Schaubel DE, Zhang H, Jia X, Pelletier SJ, Port FK, et al. Impact of 
immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. 
Transplantation 2008 06/15;85(0041-1337; 11):1601-1606.  
(37) Sung RS, Christensen LL, Leichtman AB, Greenstein SM, Distant DA, Wynn JJ, et al. 
Determinants of discard of expanded criteria donor kidneys: impact of biopsy and machine 
perfusion. Am J Transplant 2008 04;8(1600-6143; 4):783-792.  
(38) Launay JM, Del Pino M, Chironi G, Callebert J, Peoc'h K, Megnien JL, et al. Smoking 
induces long-lasting effects through a monoamine-oxidase epigenetic regulation. PLoS One 
2009 Nov 23;4(11):e7959.  




(39) Rendu F, Peoc'h K, Berlin I, Thomas D, Launay JM. Smoking related diseases: the central 
role of monoamine oxidase. Int J Environ Res Public Health 2011 Jan;8(1):136-147.  
(40) Appel DW, Aldrich TK. Smoking cessation in the elderly. Clin Geriatr Med 2003 
Feb;19(1):77-100.  
(41) Novello AC. Surgeon General's report on the health benefits of smoking cessation. Public 
Health Rep 1990 Nov-Dec;105(6):545-548.  
(42) The Surgeon General's 1990 Report on The Health Benefits of Smoking Cessation. 
Executive Summary. MMWR Recomm Rep 1990 Oct 5;39(RR-12):i-xv, 1-12.  
(43) Gharipour M, Kelishadi R, Sarrafzadegan N, Baghaei A, Yazdani M, Anaraki J, et al. The 
association of smoking with components of the metabolic syndrome in non-diabetic patients. 
Ann Acad Med Singapore 2008 11;37(0304-4602; 11):919-923.  
(44) Barregard L, Fabricius-Lagging E, Lundh T, Molne J, Wallin M, Olausson M, et al. 
Cadmium, mercury, and lead in kidney cortex of living kidney donors: Impact of different 
exposure sources. Environ Res 2010 JAN;110(1):47-54.  
(45) Thomas LDK, Hodgson S, Nieuwenhuijsen M, Jarup L. Early Kidney Damage in a 
Population Exposed to Cadmium and Other Heavy Metals. Environ Health Perspect 2009 
FEB;117(2):181-184.  
(46) Lhotta K, Rumpelt HJ, Konig P, Mayer G, Kronenberg F. Cigarette smoking and vascular 
pathology in renal biopsies. Kidney Int 2002 02;61(0085-2538; 2):648-654.  
(47) Mukamal KJ, Chiuve SE, Rimm EB. Alcohol consumption and risk for coronary heart 
disease in men with healthy lifestyles. Arch Intern Med 2006 Oct 23;166(19):2145-2150.  
(48) Gueye AS, Chelamcharla M, Baird BC, Nguyen C, Tang H, Barenbaum AL, et al. The 
association between recipient alcohol dependency and long-term graft and recipient survival. 
Nephrol Dial Transplant 2007 Mar;22(3):891-898.  





(49) Perneger T, Whelton P, Puddey I, Klag M. Risk of end-stage renal disease associated with 
alcohol consumption. Am J Epidemiol 1999 DEC 15;150(12):1275-1281.  
(50) Chung F, Yang Y, Shieh T, Shin S, Tsai J, Lee Y. Effect of alcohol consumption on 
estimated glomerular filtration rate and creatinine clearance rate RID A-1523-2010. Nephrol 
Dial Transplant 2005 AUG;20(8):1610-1616.  
(51) Seifi S, Rahbar M, Lessan-Pezeshki M, Khatami MR, Abbasi MR, Mahdavi-Mazdeh M, et 
al. Posttransplant diabetes mellitus: incidence and risk factors. Transplant Proc 2009 
Sep;41(7):2811-2813.  
(52) Hansen AS, Marckmann P, Dragsted LO, Finne Nielsen IL, Nielsen SE, Gronbaek M. 
Effect of red wine and red grape extract on blood lipids, haemostatic factors, and other risk 
factors for cardiovascular disease. Eur J Clin Nutr 2005 Mar;59(3):449-455.  
(53) Powell J, Dawkins L, West R, Powell J, Pickering A. Relapse to smoking during unaided 
cessation: clinical, cognitive and motivational predictors. Psychopharmacology (Berl ) 2010 
DEC;212(4):537-549.  
(54) Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for 
smoking cessation. Cochrane Database Syst Rev 2004(1469-493; 1361-6137; 3):CD000146.  
(55) Liu RH, Kurose T, Matsukura S. Oral nicotine administration decreases tumor necrosis 
factor-alpha expression in fat tissues in obese rats. Metabolism 2001 01;50(0026-0495; 0026-
0495; 1):79-85.  
(56) de Jonge WJ, van der Zanden EP, O The F, Bijlsma MF, van Westerloo DJ, Bennink RJ, et 
al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-
STAT3 signaling pathway. Nat Immunol 2005 AUG;6(8):844-851.  
(57) Saeed RW, Varma S, Peng-Nemeroff T, Sherry B, Balakhaneh D, Huston J, et al. 
Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during 
inflammation. J Exp Med 2005 Apr 4;201(7):1113-1123.  




(58) Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, et al. Cholinergic agonists 
inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004 
11;10(1078-8956; 1078-8956; 11):1216-1221.  
(59) Halimi JM, Philippon C, Mimran A. Contrasting renal effects of nicotine in smokers and 
non-smokers. Nephrol Dial Transplant 1998 Apr;13(4):940-944.  
(60) Zhang QL, Baumert J, Ladwig KH, Wichmann HE, Meisinger C, Doring A. Association of 
daily tar and nicotine intake with incident myocardial infarction: results from the population-
based MONICA/KORA Augsburg Cohort Study 1984-2002. BMC Public Health 2011 May 
4;11:273.  
(61) Piano MR, Benowitz NL, Fitzgerald GA, Corbridge S, Heath J, Hahn E, et al. Impact of 
smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and 
treatment: a policy statement from the American Heart Association. Circulation 2010 Oct 
12;122(15):1520-1544.  
(62) El-Mas MM, El-Gowilly SM, Gohar EY, Ghazal AR. Pharmacological characterization of 
cellular mechanisms of the renal vasodilatory effect of nicotine in rats. Eur J Pharmacol 2008 
Jul 7;588(2-3):294-300.  
(63) El-Gowilly SM, Ghazal AR, Gohar EY, El-Mas MM. Exacerbation by nicotine of the 
cyclosporine A-induced impairment of beta-adrenoceptor-mediated renal vasodilation in rats. 
Clin Exp Pharmacol Physiol 2008 Oct;35(10):1164-1171.  
(64) Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic 
acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003 Jan 
23;421(6921):384-388.  
(65) Chong IW, Lin SR, Hwang JJ, Huang MS, Wang TH, Hung JY, et al. Expression and 
regulation of the macrophage inflammatory protein-1 alpha gene by nicotine in rat alveolar 
macrophages. Eur Cytokine Netw 2002 Apr-Jun;13(2):242-249.  
(66) Costa F, Soares R. Nicotine: a pro-angiogenic factor. Life Sci 2009 Jun 5;84(23-24):785-
790.  





(67) Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, et al. Nicotine stimulates 
angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001 Jul;7(7):833-839.  
(68) Coggins CR, Frost-Pineda K, Smith DC, Oldham MJ. A comprehensive evaluation of the 
toxicology of cigarette ingredients: aromatic and aliphatic alcohol compounds. Inhal Toxicol 
2011 Jun;23 Suppl 1:141-156.  
(69) Sepetdjian E, Shihadeh A, Saliba NA. Measurement of 16 polycyclic aromatic 
hydrocarbons in narghile waterpipe tobacco smoke. Food Chem Toxicol 2008 May;46(5):1582-
1590.  
(70) Ding YS, Ashley DL, Watson CH. Determination of 10 carcinogenic polycyclic aromatic 
























In de in dit proefschrift gepresenteerde studies, wordt het effect van roken en 
nicotine op de nier bestudeerd. Diabetes, hypertensie en overgewicht zijn 
belangrijke risicofactoren voor cardiovasculaire en renale ziekten. Ook is er een 
sterke relatie tussen leefstijlfactoren en het optreden van nierziekten. Steeds 
meer studies richten zich op de rol van o.a. zoutinname, lichamelijke activiteit, 
slaap en psychosociale stress op de progressie van chronische nierziekten. 
Ondanks de ontwikkeling van nieuwe therapieën en verbeterde 
behandelingsmogelijkheden voor patiënten, bereiken nog steeds veel patiënten 
het eindstadium van nierziekten, waarbij patiënten aangewezen zijn op dialyse 
en een eventuele niertransplantatie. Om nieuwe preventieve strategieën te 
ontwikkelen, is het belangrijk dat er nieuwe behandelbare risicofactoren 
gevonden worden. Roken is één van de risicofactoren die sterk geassocieerd is 
met cardiovasculaire ziekten en met de progressie van verschillende 
nierziekten, zoals diabetische nefropathie, IgA nefropathie, hypertensieve 
nierziekten etc. In dit proefschrift hebben we de rol van roken op lichaamseigen 
en getransplanteerde nieren onderzocht.  
Roken is geïdentificeerd als een riscofactor voor de ontwikkeling en progressie 
van chronische nierziekten. Het roken van sigaretten kan zorgen voor 
nierschade door het optreden van renale vasoconstrictie, wat een afname van de 
renale doorbloeding bewerkstelligt; door toxische effecten van oxidatieve 
componenten en door blootstelling aan zware metalen. In hoofstuk 2 van dit 
proefschrift hebben we de relatie tussen het roken van sigaretten op de afname 
van nierfunctie en het optreden van afstoting van nieren na niertransplantatie 
onderzocht. Hierbij vonden we dat de nierfunctie van rokers sneller afneemt 
dan die van niet-rokers en patiënten die gestopt zijn met roken. Er was geen 
verschil in de afname van de nierfunctie tussen niet-rokers en patiënten die 
gestopt zijn met roken. In lijn met deze resultaten vonden we een verhoogd 
risico op afstoting van de nier na een niertransplantatie bij huidige rokers, in 
vergelijking met de niet-rokers en de patiënten die gestopt zijn met roken.  
 




Aangezien roken ook een belangrijke factor is in de progressie van chronische 
longziekten, hebben veel patiënten (ongeveer 60%) die een longtransplantatie 
ondergaan vroeger veel gerookt. Om in aanmerking te komen voor een 
longtransplantatie is stoppen met roken een voorwaarde. Daarom hebben we in 
hoofdstuk 3 in deze populatie het effect van het vroegere rookgedrag op de 
ontwikkeling van chronische nierziekten onderzocht. Hierbij vonden we dat hoe 
meer patiënten in het verleden gerookt hadden, hoe sneller de progressie van 
chronische nierziekten plaatsvond. Het verband tussen het vroegere rookgedrag 
en de progressie van chronische nierziekten was onafhankelijk van andere 
bekende renale risicofactoren. De observatie dat het vroegere rookgedrag 
invloed heeft op de progressie van chronische nierziekten, pleit tegen de theorie 
dat de desastreuze gevolgen van roken op de nierfunctie optreden door het 
effect van nicotine op het sympathisch zenuwstelsel. Dit moet echter wel in de 
context van de complexe pathogenese van nierfalen na longtransplantatie 
gezien worden.  
Hoewel de desastreuze effecten van roken onbetwist zijn, wordt de inname van 
kleine hoeveelheden alcohol in het algemeen als gezond gezien. Desalniettemin 
gaan roken en de inname van alcohol vaak samen. In hoofdstuk 4 van dit 
proefschrift hebben we daarom het verband tussen roken en alcoholconsumptie 
onderzocht in patiënten die een niertransplantatie ondergaan. Vervolgens 
hebben we gekeken naar het verband tussen roken en alcoholconsumptie op 
afstoting van nieren na de niertransplantatie en mortaliteit. In deze 
patiëntenpopulatie vonden we dat roken geassocieerd is met de inname van 
alcohol. Matige alcoholconsumptie bleek bij deze patiënten een positief effect 
te hebben op de mortaliteit en het ontstaan van diabetes na transplantatie. Dit 
beschermende effect kwam het sterkst tot uiting wanneer de negatieve effecten 
van het roken in de analyse werden meegenomen. Het ontstaan van diabetes na 
transplantatie wordt in de transplantatiegeneeskunde tegenwoordig gezien als 
een belangrijk verschijnsel, aangezien het optreden hiervan de overleving van 





Cigarettenrook bevat vele verschillende stoffen. Hiervan is nicotine een van de 
meest voorkomende en verslavende componenten. Nicotine wordt in 
verschillende modaliteiten toegepast om te stoppen met roken, ook bij 
nierpatiënten. Nicotine werkt via de zgn. nicotine-receptoren (nAchR), waarvan 
de α7nAchR de meest bekende en meest bestudeerde is. Agonisten van deze 
receptor zijn anti-inflammatoir. Nicotine laat inderdaad gunstige effecten zijn in 
ontstekingsziekten zoals inflammatory bowel disease (IBD), multiple sclerose 
en Rheumatoide arthritis. In hoofdstuk 5 bestudeerden wij de effecten van 
chronische nicotine behandeling op de progressie van nierfalen in een 
rattenmodel. Nicotine behandeling leidde tot een geringe verlaging van de 
proteinuria en vermindering van de nierschade in vergelijking met de 
onbehandelde controle ratten. Met name glomerulosclerose, interstitiële 
ontsteking en fibrose bleken zich minder ontwikkeld to hebben in nicotine 
behandelde ratten. Dus, alhoewel er allerlei nefrotoxische eigenschappen 
werden toegedicht aan nicotine, bleek het in dit rattenmodel nierbeschermend te 
werken. Dit is mogelijk klinisch relevant omdat het nu naast een stop-roken 
middel, ook een mogelijk medicament is om nierschade te beperken. 
In hoofdstuk 6 beschrijven wij de effecten van chronische nicotine behandeling 
op de neointima vorming in nierslagaders in twee rattenmodellen van nierfalen. 
Bij toeval ontdekten wij de aanwezigheid van een neointima in nierslagaders 
van één jaar oude Münich-Wistar-Fromter ratten. Nicotine behandeling 
gedurende 28 weken kon deze neointima vorming grotendeels voorkomen. 
Alhoewel overeenkomstige gunstige effecten van nicotine op neointima 
vorming bij primaire vaatschade al langer bekend waren, zijn wij de eersten die 
dit nu ook aantonen in nierslagaders in de context van nierfalen. Om deze 
bevinding meer waarde te geven besloten wij nicotine behandeling te starten in 
een rattenmodel van niertransplantatie, omdat dit het belangrijkste ziektebeeld 
is waar in de nefrologische kliniek neointima vorming in nierslagaders 
voorkomt. Ook in het rattenmodel van niertransplantatie bleek nicotine de 
neointima vorming in nierslagaders grotendeels te kunnen voorkomen. Omdat 




bij niertransplantatie alle zenuwen naar en van de nier zijn doorgesneden, maar 
het nicotine effect ook hier werd wargenomen, duidt dit erop dat het nicotine 
effect op de neointima vorming niet verloopt via effecten op het perifere 
zenuwstelsel, maar via een direct werking op de nier. Meer onderzoek is nodig 
om het beschermende werkingmechanisme van nicotine op de nierslagaders te 
ontrafelen. 
Samenvattend laten de studies in dit proefschrift nierbeschermende effect zien 
van chronische nicotine behandeling, in tegenstelling tot nierbeschadigende 
effecten van roken. Deze bevindingen openen interessante perspectieven voor 
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